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ABSTRACT
Macromolecular protein complexes at neuronal synapses are critical for establishing
synaptic plasticity, which is the basis of information storage in the brain. These complexes
consist of many PDZ domain-containing proteins. PDZ domains bind selectively to peptide
sequences at the C-termini of partner proteins, and they play an essential role in the regulation
of synaptic macromolecular complexes. While many PDZ domain-containing proteins are
well characterized, much remains to be learned about their binding dynamics. The goal of the
research presented herein is to gain a quantitative understanding of the complex PDZ-domain
binding dynamics through the design, synthesis, and application of sensitive and selective
biophysical probes. The peptidyl probes are based on three critical elements: solvatochromic
fluorophores, molecular caging, and multivalency.
This thesis presents the development of a systematic approach to screen for selective
solvatochromic fluorophore-based probes for class I PDZ domains, and the biophysical
characterization of probes for the PSD-95 and Shank3 PDZ domains. These probes have been
utilized to examine the effects of Shank3 PDZ domain dimerization on ligand binding in vitro,
and the quantitative results presented here implicate PDZ domain dimerization as a potential
modular control mechanism for ligand-binding in the biological context. Further development
of the probes via the application of a novel C-terminal caging strategy is also discussed.
Validation in vitro shows the utility of a C-terminal 1-(2-nitrophenyl)ethyl cage for blocking
the interaction between probe and cognate PDZ domain, and demonstrates the release of
viable probe upon photoactivation of the molecular cage.
This thesis also presents the in vivo application of PDZ domain probes, using the
simple yet powerful eukaryotic C. elegans model system. Progress toward solvatochromic
fluorophore-based probes for C. elegans Lin-10 PDZ domains is presented. Additionally, the
design and synthesis of a bivalent peptidyl inhibitor, based on the C. elegans C-terminal
sequence of STG-2 (a protein of the GLR-1 receptor complex), is discussed. This STG-2
sequence is a putative PDZ domain ligand, and its ortholog in higher eukaryotes functions in
receptor-mediated multivalent interactions with partner PDZ domains. Electrophysiological
data presented in this thesis suggest the effectiveness of the bivalent STG-2 peptide in the
inhibition of the critical C. elegans GLR- 1 neural receptor complex.
Thesis Supervisor: Professor Barbara Imperiali
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Chapter 1
Chemical Biology Approaches to the Study of Modular PDZ
Domains via Small Molecules
1.1. Introduction to Modular Domains
Modular domains that mediate protein-protein interactions involved in cellular and
receptor-mediated signaling are prevalent in biology. These domains include the PDZ, SH3,
SH2, and WW domains, all of which dynamically direct information through signaling
networks, and are often regulated via intramolecular interactions and conformational
reorganization.' From a biophysical and biochemical perspective, protein network signaling is
advantageous over signaling through distinct reactions in freely diffusible environments; the
advantages of the network approach include enhanced signaling efficiency, specificity
provided by spatial segregation, and increased sensitivity resulting from the oligomerization
of signaling complexes.2
There is structural conservation amongst each protein-interaction module family, and,
even in isolation, PDZ, SH3, SH2, and WW domains are highly stable alone, due to their
small size and well-defined protein architecture (see Figure 1.1). Additionally, the
recognition events mediated by these conserved domains are relatively transferable, allowing
for the study of the native behavior of these modular domains alone or in synthetic
recombination with other protein domains.3 These favorable physical properties, taken
together with the critical roles the domains play in protein-protein interaction networks, point
to these modules as optimal targets for chemical biology. Here a brief overview of each of
these families of modular domains will be presented, followed by descriptions of the
approaches that chemical biologists have taken to study PDZ domains in particular.
SH2 Domain
Figure 1.1. Ribbon diagrams of representative PDZ, SH3, SH2, and WW domain crystal
structures. Clockwise from top left: PSD-95 PDZ3 complexed with KKETPV peptide, PDB
entry 1TP3; Grb2 SH2 domain complexed with pYVNVP peptide, PDB entry 3N8M; Abl
kinase SH3 domain complexed with Pro-rich peptide, PDB entry lABO; Dystrophin WW
domain complexed with p-dystroglycan, PDB entry 1EG4.
The PDZ domain is named after the first representative domains of its family that were
identified: PSD-95/SAP90, Discs-large, and ZO-1. It is a small, -100-residue domain that
typically binds to ligands represented by the C-terminus of partner proteins through a well-
defined binding pocket. These types of domains are abundant in various species, and are
among the most common protein domains represented in sequenced genomes.4 PDZ domains
are modular, and consist of 5 or 6 P-strands and 2 or 3 a-helices. 5 The binding specificity of
.
.
.
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PDZ domains is determined by the interaction of the domain with the side chain of the -2
ligand residue (where, by convention, position 0 is the C-terminal residue and the residue
numbers decrease from the C-terminus in the N-terminal direction of the sequence, as shown
in Figure 1.2).
0 R 0 R 0 R 0
J H J H J H
N N N OH
H = H = H-
O R 0 R 0 R
-5 -2 0
Figure 1.2. PDZ domain ligand numbering convention.
PDZ classification is based upon the identity of critical residues in the binding ligand:
class I PDZ domains bind ligands with a Ser or Thr at the (-)2 position, class 1I a hydrophobic
residue, and class III an Asp or Glu residue. The ligand C-terminal carboxylate is critical for
binding in most cases, as are some more N-terminal residues that contribute to binding
specificity.4 PDZ domain modules are prevalent in multi-domain scaffolding proteins,
especially in the postsynaptic density of neuronal excitatory synapses. One major example of
these PDZ-domain containing scaffolding proteins is the postsynaptic density protein 95
(PSD-95), which is involved in organization of glutamate receptors and in the dynamic
trafficking of synaptic proteins. The PDZ domain modules of PSD-95 aid in the assembly of
macromolecular protein complexes at the synapse, allowing for this protein to regulate
synapse strength.6
Another modular protein-protein interaction domain is the Src homology 3 (SH3)
domain, one of the best-characterized protein-interaction modules, which is a -60-residue
domain that is found across many protein families. It exhibits a characteristic p-barrel fold,
and the domain surface bears a relatively flat, hydrophobic ligand-binding surface. The SH3
domain typically binds ligands with a ProXaaXaaPro tetrapeptide motif, which adopts a
specific helical conformation, although there are examples of SH3 ligands without this
consensus motif. The binding affinity and selectivity is quite low between SH3 domains and
ProXaaXaaPro motif-containing peptides or proteins, implying that other forces lead to better
affinity and selectivity in these systems.' One of the most prominent examples of an SH3-
mediated interaction comes from the Src tyrosine kinase itself. The interaction of the
ProXaaXaaPro motif helical linker region of Src with its SH3 domain constrains this kinase
into an inactive conformation. In this case of intramolecular binding, the effective local
concentration of ligand and SH3 domain is high, favoring the SH3-bound inactive form even
though the binding affinity is modest.-10
One of the smallest yet most versatile protein-interaction modules, the WW domain,
interacts with proline-containing ligands, and is named after the two defining tryptophan (W)
residues it contains spaced 20-22 residues apart. The interaction of short proline-containing
motifs with the WW domain relies upon an interaction between the ligand proline and two
WW domain stacked aromatic residues, one of which is a conserved tryptophan." One
prominent example of this small domain in cell biology is the role it plays in regulating the
connections between the extracellular matrix and the cytoskeleton. The cytoplasmic tail of
the membrane-associated dystroglycan binds to the WW domain of the cytoskeletal protein
dystrophin, which in turn interacts with the actin cytoskeleton.12 ,13
Other modular domains are evolved to recognize phosphorylated substrates, which
play critical roles in cell signaling. The Src homology 2 (SH2) domain is a -100-residue
domain found in a variety of protein families, from kinases to adaptor proteins to transcription
factors. The SH2 domain fold comprises a central anti-parallel p-sheet sandwiched between
two c-helices, and the positively charged pocket that is created by this fold binds to the
phosphotyrosine residue of the ligands to which it binds. The specificity of SH2 domains for
their respective ligands come from specific interactions between the domain and about 3-6
residues C-terminal to the phosphorylated tyrosine." SH2 domains often recognize
autophosphorylated tyrosine residues of receptor tyrosine kinases such as Src, sometimes in
an intramolecular fashion. In the case of the autoinhibited Src-family enzymes, the Src SH2
domain binds to a C-terminal phosphotyrosine site within the kinase, which conformationally
allows for the SH3 domain to bind its intramolecular ligand. The SH3 and SH2 domains of
Src work in concert to achieve this autoinhibition.
While much is known about the function and binding properties of the modular
protein-interaction domains mentioned here, there remain many questions to be answered and
important applications to be explored. One focus of particular importance is the development
of therapeutics and chemical probes that either inhibit or report on specific protein-protein
interactions involving these well-defined protein modules. 5 The field of chemical biology is
well equipped for this type of challenge, and much headway has been made on small
molecule binders of PDZ, SH3, WW, and SH2 domains. Here the advances that have been
made in the development of small molecule probes and inhibitors of PDZ domains in
particular will be discussed. Peptide-based probes and inhibitors, including blocking
peptides, peptidomimetics, fluorescent peptides, and cyclic peptides, as well as non-peptidyl
small molecule antagonists, have been developed; the uses of these molecules to address
unanswered biological questions and to move toward therapeutic applications will be
reviewed here. Figure 1.3 summarizes the PDZ domain-containing proteins and their ligands
discussed in this chapter.
PDZ Domain (s) Ligand(s) PDZ Function Inhibitor(s)
Domain
Class
PSD-95 AMPAR interacting I glutamate receptor NR2B-based
(postsynaptic stargazin, organization; blocking peptides;
density protein NMDAR subunits trafficking of NR2B-based
95) NR2A/NR2B, synaptic proteins; peptidomimetics;
GluR6 kainate target for chronic fluorescent probes;
receptor, pain treatment cyclic peptides;
small molecules;
neuronal nitric NR2A/NR2B and
oxide synthase nUOo stargazin-based
dimers
PICK1 AMPAR subunit GluR2 11 trafficking of GluRl-based
(protein kinase C AMPARs blocking peptide;
a bidingsmall molecules
protein)
G=P1 AMPAR subunit GluR2 II trafficking and GluRl-based
(glutamate recycling of AMPARs blocking peptide
receptor
interacting
protein) ___________
N M 1 melatonin receptor III melatonin receptor nonnative peptide
(multi PDZ domain Iff(l) signaling
protein 1)
Erbin epidermal growth II Erbb2 function and nonnative peptide
(Erbb2 factor receptor localization
interacting erbb2 (E )
protein)stargazi
Sank3 AMPAR subunit GluR2, I structural fluorescent probes
(SH3 and multiple guanylate kinase framework of the
ankyrin repeat associated protein postsynaptic
domains 3 GKAP density; bridge
protein) between structural
proteins and
surface receptors
Syntropin neuronal nitric n/a scaffold for cyclic peptides
(dystrophin oxide synthase NOS proteins involved
associated in cell signaling
protein)
ErbI-3 tumor supressor I regulation of PTEN indole-based small
(membrane fTt suppressor molecules
associated functions
(uanylate kinase-
related protein) associatedprotei
NHE-1 tumor supressor I G protein-coupled indole-based small
(Na/H regulatory FIZ' trafficking molecules
factor- protein) G-catenin
DVl Frizzled receptors n/ta transduction of Wnt small molecules
(Dishevelled pathway signals
protein)
RhoEF receptor plezLin 8 guanine nucleotide plexin B-based
(Rho guanine exchange factor in dimers
nucleo tide Rho-mediated
exchange factor signaling
protein)
Figure 1.3. PDZ domains, cognate ligands, and inhibitors discussed in this chapter.
References are given in the text. a n/a = PDZ domains that bind cognate ligands in non-
canonical manners, and are not classified in any of three canonical PDZ domain classes.
1.2. C-terminal blocking peptides for PDZ domain inhibition
In principle, if a protein-protein interaction relies upon a distinct interaction site, such
as the binding groove of a PDZ domain, this interaction should be modulated or inhibited by
"blocking peptides." In the case of the PDZ domains, these peptides mimic the C-terminus of
a PDZ domain ligand, and in unaltered form are simply the terminal -10 amino acids of the
ligand sequence, sometimes with a cell permeabilizing sequence.16 Since the interaction of the
PDZ domain and ligand most often relies exclusively on these terminal residues, blocking
peptides should'bind with close to the same affinity as their parent proteins from which they
are derived. Many successful examples of unmodified blocking peptides have been reported,
and have been used to study the effects of competition with specific PDZ domain - ligand
interactions in vitro and in the native cellular environment.
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Figure 1.4. Representative examples of diverse inhibitors and probes for PDZ domains. PDZ
domain shown is PDZ3 of PSD-95 protein complexed with KKETPV peptide ligand, PDB
entry 1TP3. References are given in the text.
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C-terminal peptides based on the PDZ binding motif of the glutamate receptor subunit
GluR2 have been used to investigate the roles of postsynaptic protein kinase C alpha binding
protein (PICKI) and glutamate receptor interacting protein (GRIP) on a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors.17 -19 Specifically, a peptide
corresponding to the wild-type GluR2 C-terminus blocks binding of both PICK1 and GRIP to
the GluR2 subunit. However, a mutated Ser880 phosphorylated GluR2 C-terminus
(Ser880Glu) only blocks PICKI from interaction with GluR2. Patch-clamp studies, which
allow for the electrophysiological investigation of single or multiple ion channels in cells,
have shown that the wild-type GluR2 C-terminal peptide (see Figure 1.4) causes an increase
in AMPA receptor currents, while identical studies with the Ser88OGlu peptide have shown
no such effect. This indicates that blocking of both the PICK1 and GRIP interactions with
GluR2 are necessary for inhibition of long-term depression (LTD), a lasting decrease in
synaptic effectiveness that follows some types of electrical stimulation in the brain.'"
In addition to the study of AMPA receptors, the study of N-methyl D-aspartate
(NMDA) receptors has been greatly aided by the use of blocking peptides that mimic PDZ
domain-binding ligands. NMDA receptors are known to mediate ischemic brain injury,20 and
while inhibiting NMDA receptors directly has proven to be a failed strategy for the treatment
of specific brain disorders, an alternative is to block downstream excitotoxic signaling without
completely blocking NMDARs and the corresponding neurotransmission. A blocking peptide
consisting of the C-terminal residues of the NR2B receptor subunit fused to the cell-
membrane transduction domain of the HIV-1 TAT protein, 21, 22 which allows for cell
permeability, has been shown to successfully reduce the susceptibility of neurons to
excitotoxicity and ischemia. Even though there are many possible binding partners for this
blocking peptide, the authors determined biochemically that it bound selectively to PSD-95 at
low concentrations, and confirmed that only neurons lacking PSD-95 (but not other PSD-95
family members) exhibited reduced vulnerability to NMDA toxicity.' This demonstrates that
while blocking peptides based on the C-terminus of PDZ domain ligands may have multiple
binding partners, general biochemical analyses and cellular investigations can define a
maximum threshold concentration under which the blocking peptides are selective for the
inhibition of particular interactions.
Additional approaches can provide blocking peptides with higher affinity and
selectivity, especially in the context of promiscuous PDZ domain ligands that often bind to
multiple partner proteins. Most blocking peptides are based on the wild-type C-terminus of a
PDZ domain ligand, and high-throughput screens based on support-bound PDZ domain
peptides,24 as well as microarrays of PDZ domains analyzed in the presence of peptide
ligands, 25 can reproduce these native interactions. Variants of ligands that bind to specific
PDZ domains can be rationally engineered and screened via the same technologies, to yield
peptides that are optimized for both specificity and affinity.24 Rational (focused) and random
libraries of peptides can be subjected to iterative selection-enrichment cycles against
particular PDZ domains in C-terminal peptide phage display, allowing for the selection of
unnatural peptide ligands. This particular approach does not require chemical synthesis of the
peptides until the later validation stages of the process, and has been employed to successfully
identify a ligand for the tenth PDZ domain of the scaffolding multi-PDZ domain protein 1
(MUPPI) with a two-fold affinity improvement over the native C-terminal peptide ligand, 26 as
well as a 0.02 tM ligand for the Erbb2 interacting protein (Erbin) PDZ domain, one of the
highest affinity peptide ligands reported for a PDZ domain.27 Overall, there are many
available strategies for screening and optimizing blocking peptides, which have been utilized
to address critical questions regarding biological protein-protein interaction systems such as
those involving PDZ domains.
1.3. Nonnative Peptides as PDZ Domain Ligands
While C-terminal blocking peptides have been used successfully to investigate the
roles of many PDZ domains in the biological setting, many nonnative PDZ domain ligands
have also been designed and pursued, and some of these address shortcomings of native
blocking peptides. An overview of the main classes of these nonnative PDZ domain ligands
is presented here, including the methods by which they were developed and the information
regarding PDZ domain function that has been garnered with their application.
Peptidomimetics
A peptidomimetic approach to develop modified peptides has been used successfully
in several studies. For example, it was used to develop inhibitors for the scaffolding protein
al-syntrophin PDZ domain that are more potent than the corresponding native peptides.
These modified peptides, one of which is shown in Figure 1.4, are protease-resistant
peptidomimetic structures incorporating conformationally constrained amino acid surrogates,
which reproduce the hydrogen-bonding pattern and side-chain functionality of a s-strand.'
The peptidomimetic approach has also proven efficacious for the development of
small molecules to inhibit the interaction between NMDA receptors and the PDZ domains of
PSD-95, a critical target interaction for the treatment of ischemic brain disorders. Previously-
discussed blocking peptide studies identified a TAT-NR2B inhibitory peptide, and this
template was used for the development of smaller potential drug targets. Specifically,
truncation to a tetrapeptide, N-terminal modifications, and the optimization of side chains
with both natural and unnatural functionalities (see Figure 1.4) all led to the most potent
inhibitor of the PSD-95 / NMDA receptor interaction, with a 20-fold tighter affinity than the
parent TAT-NR2B peptide.2 9
In another approach, involving the rational modification of hexapeptide ligands for
PSD-95, researchers utilized structural information from an x-ray crystal structure of ligand
bound to PDZ domain 3 of PSD-95 to extend the side chains of specific residues into
available space in the PDZ domain-binding pocket. A small library of modified ligands was
made via the coupling of a panel of organic acids onto acyl acceptors in the peptide sequence,
leading to multiple ligands with submicromolar affinities for this modular domain. 29 These
molecules have been validated using in vitro binding studies, and the strong affinities they
exhibit for the third PDZ domain of PSD-95 point to their potential as cellular probes and
drug targets, most likely with stability toward cellular proteases.
Fluorescent Peptides
A different approach to the development of cellular PDZ domain probes relies on
fluorescence as a method for detection of binding to and inhibition of target PDZ domains.
Fluorescence polarization has been widely utilized to determine binding constants of PDZ
peptide ligands identified from larger peptide screens, often via the attachment of the
fluorophore to the N-termini of the peptides. 5 This strategy allows for the quantification of
binding affinity and, in addition to isothermal titration calorimetry, is one of the more widely
used techniques to quantify peptide-protein dissociation constants. However, not all
fluorimeters are equipped for fluorescence polarization measurements, and the low
fluorescence signal often afforded by this technique can lead to issues with data interpretation,
as the signal to noise ratio can be rather low. Additionally, fluorescence polarization
measures the presence of any complex, not just the targeted protein-ligand complex; since the
binding site is not necessarily known or targeted, false positive results can be obtained from
this method.
A parallel fluorescence-based approach that avoids this concern is the incorporation of
small solvatochromic fluorophores into the PDZ ligand as part of the design, effectively
creating a fluorescence reporter for binding to PDZ domains and a potential PDZ domain
inhibitor (see Figure 1.4). This strategy has been successfully applied to the development of
probes for class I PDZ domains including those of PSD-95 and SH3 and multiple ankyrin
repeat domains 3 (Shank3) synaptic proteins. 30 The incorporation of
dimethylaminophthalimide chromophores in the probes aided in the screening and
optimization of the ligands, and functioned as reporters of binding. In this case, incorporation
of the solvatochromic moiety at appropriate positions actually increased binding affinity of
the probes to partner PDZ domains by an order of magnitude, as compared to the native
parent peptides. Overall, this strategy yielded fluorescent peptide probes with enhanced
ability to inhibit targeted PDZ domain-ligand interactions, 3 0 and will be discussed in detail in
Chapter 2.
Cyclic peptides
In addition to fluorescent peptides and peptidomimetics, cyclic peptides have shown
promise as PDZ domain binders and inhibitors. Cyclization enhances stability to proteases,
and therefore increases the duration over which the peptides can inhibit PDZ domain-ligand
interactions in vivo. The PDZ domains of PSD-95 have been targeted with blocking peptides,
peptidomimetics, and fluorescent peptides, and multiple cyclic peptide designs have proven to
be effective binders and inhibitors of these domains. 3134
In order to introduce the macrocycles onto native peptide scaffolds, researchers have
replaced the less critical (-)1 and (-)3 residues of known PSD-95 PDZ domain ligands with
residues that can be tethered via bridging elements. Cyclic scaffolds containing lactam
bridges of varying lengths have been synthesized via the reaction of a-, P-, or y-amino acids
with amino- and carboxy-functionalized side chains of residues at the (-)1 and (-)3 positions
in PDZ domain ligands.3 1 , 32 Organic biscarboxylic acids have also been incorporated as
bridges, via the formation of amide bonds with two amine-presenting side chains at the (-)1
and (-)3 positions of the peptide.3 3 An example of this type of macrocycle is given in Figure
1.4. Each of these strategies allows for the systematic variation of ring size and rigidity of the
resulting macrocycles. In one particular case, a lactam bridge-based cyclic analog for the first
PDZ domain of PSD-95 produced a 10-fold enhancement in binding affinity over its parent
linear peptide ligand. Studies showed that this cyclic scaffold disrupted the interaction of
the GluR6 kainate receptor subunit with PSD-95 five- to ten-fold more effectively than the
parent linear peptide. The cyclic peptide was also found to disrupt the clustering of kainite
receptors for longer periods of time than the linear peptide, pointing to enhanced proteolytic
stability.
A cell-permeable version of this cyclic peptide, referred to as CN2097, was utilized to
study the effects of PSD-95 PDZ domain inhibition on neuropathologic conditions. 34 PSD-95
is thought to be a target for managing many neurological conditions including chronic pain,
and therefore injection of this peptide into rats was predicted to interfere with physiologic
phenomena related to pain. Specifically, this cyclic compound was reported to mitigate
several phenomena known to promote central sensitization, which is an undesired enhanced
responsiveness of certain neurons in the central nervous system to normal input. Application
of this inhibitor showed signs of halting chronic pain, through attenuation of neuronal firing in
affected rats.34 Overall, bridged cyclic peptides show promise biochemically and in vivo as
PSD-95 PDZ domain inhibitors with heightened resistance to protease degradation.
A different approach to the design of cyclic peptide inhibitors veers further from the
traditional definition of a PDZ domain ligand, as it yields ligands that lack a free C-terminal
carboxylate. Specifically, phage-displayed combinatorial libraries have yielded cyclic
peptides without free C-termini that bind the syntrophin PDZ domain." In this case, it was
found that peptides with two Cys residues forming an intramolecular disulfide bond could act
as C-terminal peptide mimetics and bind to syntrophin, even while fused to the N-terminus of
a bacteriophage via their C-termini. The intrachain disulfide bonds of these peptides were
necessary for binding to syntrophin, and like cyclic ligands for other protein classes derived
from phage-displayed libraries, these peptides appear to act as structural mimics of natural
ligands. While the peptides identified for the syntrophin domain display weaker affinities
than the natural ligands,35 the pursuit of structural ligand mimics instead of primary sequence
ligand mimics may prove useful for the generation of inhibitors for this and other PDZ
domains.
1.4. Small Molecule Inhibitors for PDZ Domains
While peptide-based inhibitors are both useful for probing PDZ domains and as
potential drug targets, small molecule antagonists tend to be more efficacious as drugs. The
majority of current pharmacotherapeutics target transmembrane receptor proteins, which are
critical components of disease-modulating signaling pathways. However, an alternative
strategy is the development of drugs for specific protein-protein interaction modules within
those pathways. This approach should lead to less undesired side effects, since only specific
signaling pathways mediated by each receptor would be affected.36 37 Since PDZ domains are
implicated in many neurological-based disorders, they have become an attractive target for
drug development.
Rational inhibitor design
Small molecule reversible inhibitors of class I PDZ domains have been successfully
developed through rational design.38 ' Researchers designed a generalizable indole scaffold
for PDZ-domain binding, which could be substituted with functional groups mimicking
critical peptide ligand side chains. Through molecular modeling analysis, they were able to
define the geometry of the side chain functionalities with respect to each other, and
incorporate them on the indole scaffold to achieve a similar spatial arrangement. 38 This
elegant strategy yielded a reversible inhibitor for the membrane associated guanylate kinase-
related (MAGI-3) PDZ domain, yet the molecule also bound to other class I PDZ domains.
This is not surprising given the promiscuity of PDZ domain ligands among different classes,
and given the inhibitor design, which relies upon critical 0 and (-)2 residue side chains that
are shared among each class of ligands. Due to this lack of selectivity, small changes in the
substitution of the indole inhibitor scaffold yielded an inhibitor of the G protein-coupled
trafficker Na/H regulatory factor-1 (NHERF-1) PDZ domain with similar promiscuity."
Interestingly, a derivative of this inhibitor containing an indole-3-methanol functionality
yielded an electrophilic probe that could covalently label the conserved His residue of class I
PDZ domains such as MAGI-3 and NHERF-1 (see structure in Figure 1.4).4 Although not
selective among class I PDZ domains, this type of probe could be useful for proteomics
studies involving PDZ domains, and the general design could be applied to create probes for
other classes of PDZ domains. Optimization would be necessary to apply this type of rational
design strategy to the development of specific PDZ domain inhibitors, although this research
marks an important step toward the rational design of small molecule inhibitors of protein-
protein interactions.
Screening for small molecule inhibitors
NMR spectroscopy-based screening,4 1 often in combination with computational
structure-based ligand screening,42 43 has proven useful in the identification of small molecule
PDZ domain inhibitors. Small molecule inhibitors for the Dishevelled (Dvl) PDZ domain
have been identified in this manner.42 '4 Dvl is involved in the Wnt signaling pathway, and
helps to transduce Wnt signals from the receptor Frizzled to downstream components. Low
micromolar binders of Dvl identified through these computational and NMR-based screens
were shown to effectively block Wnt signaling in vivo.43 Indeed, targeting of the PDZ domain
of Dvl with small molecule inhibitors effectively inhibits Wnt signaling, both offering a tool
for dissecting the Wnt pathway components, as well as a potential drug target.
A select number of small molecule inhibitors of PDZ domain interactions that also
show promising effects in vivo have been identified via chemical library screens.44'45 These
small molecules exhibit promise as therapeutic targets for the management of neuropathic
pain. One of these, a small molecule inhibitor of the PICK1 PDZ domain (see Figure 1.4),
displays a low micromolar affinity akin to that observed for native PICKI ligands, and is
specific for this particular PDZ domain. PICKI binds to the C-terminus of AMPA receptors,
and is involved in the trafficking of the GluR2 subunits of these receptors. Pretreatment of
cultured hippocampal neurons with the identified small molecule inhibited
coimmunoprecipitation of GluR2 and PICK1, and accelerated the recycling of GluR2. In
addition, this small molecule blocked long-term depression and long-term potentiation in
neurons (the decrease and enhancement in neuronal signal transmission, respectively),
demonstrating its ability to inhibit synaptic plasticity."
Another promising small molecule for the treatment of chronic pain inhibits the
interaction between neuronal nitric oxide synthase (nNOS) and PSD-95 PDZ domains
(structure given in Figure 1.4).45 This small molecule was shown to disrupt in vitro binding
between these two proteins, and was efficacious in cell-based and in vivo pain models.
Additionally, there is approximately a 100-fold difference between the estimated ICao values
of this compound for inhibiting thermal hyperalgesia (a measure of neuropathic pain) and the
undesired inhibition of motor coordination, unlike the best 3- to 6-fold difference found for a
reported NMDA receptor antagonist.45 These types of small molecule drugs show promise in
terms of potency as well as specificity for the particular signaling pathways of interest, since
they target protein-protein interactions further downstream from receptors.
1.5. Probing Multivalency and Oligomerization of PDZ Domains
Thus far, progress in the development of binders for single PDZ domains has been
discussed. However, PDZ domain - ligand interactions are complex phenomena that are
regulated by many factors, including presentation of multiple PDZ domains along single
polypeptide chains, as well as the ability to homo- and hetero-oligomerize. In order to best
enhance the ligand-binding affinity of PDZ domains, properties such as oligomerization have
been exploited. Figure 1.5 depicts these variations of multivalent interactions.
PDZ domain dimer PDZ domain tandem
Figure 1.5. Schematic of two different multivalent PDZ domain interactions. Left: dimer
(made up of two PDZ domains from different protein chains). Right: tandem domains
(interacting domains from the same protein chain).
Monovalent fluorescent probes, which were introduced earlier, have been used to
quantify the effects of Shank3 PDZ domain dimerization on ligand-binding affinity, as will be
discussed in Chapter 4. The dissociation constant of monovalent ligands was shown to
decrease 8- to 30-fold for dimeric Shank3 PDZ domain (in comparison to monomeric
domain)."6 This quantitative information reveals the critical role of oligomeric interactions in
the binding of peptidyl probes, which can be efficacious in the design of higher affinity PDZ
domain binders.
Toward that aim, there have been reports of bivalent ligands designed to bind to either
dimeric PDZ domain targets47 or tandem PDZ domains of the same protein.4 8'49 It has been
suggested that hetero- and homo- oligomerization control the activity of the Rho guanine
nucleotide exchange factor (RhoGEF) PDZ domain. Additionally, clustering of plexin B, a
ligand for the RhoGEF PDZ domain, is of functional importance in Rho-mediated signaling.
For these reasons, the interaction between a dimeric form of RhoGEF PDZ domain and a
bivalent peptide mimicking the dimer of the plexin B receptor ligand for RhoGEF was
investigated. Peptide dimerization was achieved via cross-linking of the N-terminal ends of
peptides with PEG (polyethylene glycol) spacers, keeping the critical C-termini available for
binding (see Figure 1.4). These bivalent ligands bound to the dimeric PDZ domain with an up
to 20-fold increase in affinity compared to the simple monomeric protein and ligand system.'
Tandem PDZ domains typically function together to bind ligands in a cooperative
manner. The first two PDZ domains of PSD-95 and its family of proteins are linked by a
conserved peptide linker of less than five amino acids, and the corresponding C-terminal
peptide-binding grooves are structurally aligned in a manner for preferential binding to
multimeric membrane PDZ domain ligands.5 ' As such, these tandem domains present
validated targets for bivalent peptide ligands. Bivalent PEG-linked peptides, based on the C-
terminal residues of the NMDA receptor subunit ligands for PSD-95, bind the PSD-95 tandem
via a two-step process, and show increased affinity relative to the parent NR2A/NR2B
monomeric ligand.48 Bivalent triazole-linked peptides (shown in Figure 1.4) synthesized via
click chemistry, based on the C-terminus of the membrane-bound Stargazin ligand, have also
been developed and tested.4 9 Studies in vitro and in a cellular FRET-based model show
enhanced affinity of the dimer for the PSD-95 tandem as compared to the parent monovalent
peptide. These bivalent ligands were also successfully used as PSD-95 PDZ domain
inhibitors in rat hippocampal neurons, clearly showing effective disruption of AMPA receptor
complexes.4 9 Overall, these various bivalent ligands represent a critical step toward higher
affinity probes and inhibitors of PDZ domains, and demonstrate the utility and necessity of
biological contextualization in the design of inhibitors.
1.6. Perspectives and Dissertation Objectives
Protein-protein interactions have become of interest as targets for inhibitors and
therapeutics due to their prevalence in biology and the specific roles they play in normal and
disease states. Protein-protein interactions involving the PDZ domain are well defined,
typically depending on the interaction between the PDZ binding groove and the C-terminal
peptide sequence of the partner protein ligand. In this thesis, the design, development,
validation, and application of tools to study these important domains will be presented.
Specifically, fluorescent peptidyl probes for PDZ domains have been developed, which both
detect cognate binding and out-compete natural PDZ domain-ligand interactions. These
peptide inhibitors have been further developed as caged probes (using a novel caging
approach), which only bind after uncaging with ultraviolet light and release of the "active"
ligand, and are therefore temporally and spatially controllable. The fluorescent probes have
been utilized in vitro to study the behavior of a specific PDZ domain and the effects of
domain dimerization on C-terminal peptide binding, and the fluorescent probes have also been
applied to in vivo studies in C. elegans. Lastly, bivalent peptides have been developed and
utilized for the investigation of C. elegans AMPA receptor complexes and the interactions
between their component proteins. These efforts, as well as ongoing research and future
directions of study, will be discussed in detail in the forthcoming chapters.
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Chapter 2
Peptide-Based Fluorogenic Probes for Dynamic Studies of
Class I PDZ Domain-Mediated Interactions
Portions of this chapter have been published in the Journal of the American Chemical Society'
as noted in the text. Copyright C 2009, American Chemical Society.
Introduction
The development of a general strategy for the design, synthesis and evaluation of
fluorogenic probes for PDZ domains is presented here. These probes are based in part on
natural ligand sequences and incorporate an environment-sensitive fluorophore to report
specific binding events. This strategy necessitates appropriate placement of the
solvatochromic group within the ligand sequence, such that changes in the local environment
due to interactions with cognate domains result in significant modifications of the
fluorescence properties of the fluorophore, as depicted in Figure 2.1. Chromophores of the
dimethylaminophthalimide family (4-DMAP, 2 6-DMN, 3 and 4-DMN 4) exemplify these
properties and have previously been applied to the development of sensors for small protein
domains such as SH2 (phosphotyrosine-binding) domains.3 In this case, placement of the
fluorophore adjacent to the conserved binding determinants has afforded sensors with modest
(-10-fold) signal enhancement. Alternatively, solvatochromic fluorophore-based probes have
been developed for pSer/pThr-binding domains (14-3-3 proteins),2'5 calmodulin,4 and class I
MHC proteins,6 by replacement of a conserved hydrophobic aromatic ligand residue which is
known to interact with a defined site on the cognate binding protein. However, not all protein
interaction domains allow for such a replacement approach to be utilized, as the domains may
either not rely upon defined hydrophobic interactions or, alternatively, the native hydrophobic
residues may constitute critical specificity determinants that cannot be modified. PDZ
domains typically fall into both of these categories and therefore necessitate the development
of a different, more general strategy to generate optimized fluorescent probes.
-DAPndM
0 0 H
HA H H
N N N N
H H
-2'\OH
-2
C
SO
ka>
0,
C
0
OH
43 4N 332 SU S2 4n 2
Wavelength (nm)
Figure 2.1. Probe design and function. A) Optimized fluorescent ligands report binding to
partner PDZ domains by dramatic changes in emission intensity and maximum Xem. B)
Representative structure of fluorogenic probes with 4-DMAP fluorophore (on highlighted
residue), numbering convention for PDZ domain ligands (0 = C-terminal residue, residue
numbers decrease from there; critical residues 0 and (-)2 are highlighted in red).
Fluorescence emission spectra of probe 12 in the unbound (purple) and Shank3-bound
(orange) states.
There is significant interest in probing PDZ domain-mediated interactions of
postsynaptic density scaffold proteins in neurons. More specifically, the target proteins in this
study are PSD-95 and Shank3, representative members of the MAGUK/SAP' and
Shank/ProSAP8 families respectively. Both proteins contain one or several class I PDZ
. ................... _ ...............  . .. .. .. ... ... ........  .. .......... .
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domains. In contrast to previous studies, where a defined hydrophobic pocket in the cognate
domains immediately suggested an ideal position to insert the environment-sensitive
fluorophores, 9-12 PDZ domains accommodate a wide variety of ligands conforming to specific
consensus sequences defined by residues at positions 0 and (-)2, and do not provide
conserved residues to substitute without affecting critical specificity determinants. (A
schematic of the PDZ domain ligand numbering convention is shown in Figure 2.1B.)
Furthermore, apart from the hydrophobic pocket, which accommodates the C-terminal
aliphatic ligand residue, PDZ domains lack any obvious non-polar site flanking the binding
groove. Hence a systematic approach was utilized to identify probes that efficiently report
binding. The design strategy included: (1) development of a peptide library to screen for the
optimal fluorophore placement, and (2) screening of probes with the fixed fluorophore
position for improved affinity and specificity.
Results and Discussion
2-1. Design and Synthesis of a Library of Probes'
The design of the probes for PDZ domains is based in part on natural PDZ domain
ligand sequences, and incorporates a 4-DMAP environment-sensitive fluorophore to report
specific binding events, as depicted in Figure 2.1. Use of natural ligand sequences affords
native sequence specificity. Although structural studies indicate that key interactions with
PDZ domains primarily involve the last four ligand residues, some data suggest that
additional residues may also be important, 3 which is why studies focused on the terminal 10
residues of the native ligands in the targeted probes. The protein PDZ domains and their
partner ligands (from which C-terminal peptides were fashioned) utilized in these studies are
summarized in Table 2.1.
Entry PDE Domain (a) Partner Ligand(s)
1 PSD-95 PDZ12 Stargazin, R2A, CRIPT
2 PSD-95 PDZ3 Stargazin
3 SAP-97 PD212 Stargazin, R2A, CRIPT
4 SAP-97 PDZ3 Stargazin
5 SAP-102 PDZ12 Stargazin, NR2A, CRIPT
6 SAP-102 PDZ3 Stargazin
7 Shank3 PDZ GluRI
8 PICXI PDZ
9 GRIP PDZ45
10 mGluR7a
Table 2.1. PDZ domain and ligands used in these studies. PDZ domains in black are all class
I. Class II PDZ domains used for control testing are shown in red, as is a control ligand.
Fluorescent peptides based on the terminal 10 residues of PDZ domain ligands were
synthesized, with incorporation of the fluorophore at varying sites along the peptide, as
delineated in Scheme 2.1. Specifically, the peptides were synthesized by standard 9-
fluorenylmethoxycarbonyl (Fmoc)-based solid phase peptide synthesis (SPPS) on the highly
acid labile TGT resin, with incorporation of the commercially available, allyloxycarbonyl
(Alloc) orthogonally protected amino acids Fmoc-Dap-(Alloc), Fmoc-Dab-(Alloc), and
Fmoc-Orn-(Alloc). Following Alloc deprotection, 4-(NN-dimethylamino)-phthalic anhydride
2, synthesized according to the literature and Scheme 2.2,2 was coupled onto the peptide to
yield 3. The resulting peptide was treated with HBTU/HOBt and base for ring closure, and
released from the TGT resin with a free C-terminal carboxylic acid. Subsequent HPLC
purification yielded the desired probe 4, confirmed by analytical HPLC and matrix-assisted
laser desorption/ionization time-of-flight (MALDI-TOF) analysis.
Scheme 2.1. Synthesis of general fluorescent probe 4 (n = 1, Dap; n = 2, Dab; n = 3, Orn).
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Scheme 2.2. Synthesis of 4-(NN-dimethylamino)-phthalic anhydride 2.
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Figure 2.2 shows the Dap, Dab, and Orn residues with the appended 4-DMAP
chromophore. All of these residues were incorporated into the probes for screening, since
tuning of the linker length between the peptide backbone and the environment-sensitive
fluorophore is critical to probe function. Results from the screens, presented later in this
chapter, will demonstrate the necessity of linker length tuning.
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Figure 2.2. Three 4-DMAP-derived residues incorporated into the PDZ domain probes.
Each differs solely by the number of methylene units in the linker between the backbone of
the peptide and the fluorophore. Dap = diaminopropionic acid, Dab = diaminobutyric acid,
Orn = ornithine.
All of the peptides that were synthesized and analyzed are compiled in Table 2.2,
along with their MALDI-TOF mass characterization and analytical HPLC retention times.
Purity (>95%) of the fluorescent peptides was judged by analytical HPLC. These peptide
sequences and the choices of fluorophore position will be discussed in section 2.3.
# Origin Peptide 3equance* PozinaUa Mass Mes*
- obtained
1 Stargasin jTEk3RRT"-aV_ CSHeNA 0 11 1332.7 1333.5 21.8
2 Stargasin STANMRTA o CIBus d40 1328.7 1330.5 21.7
3 Stargazin _NThU LaTTPVe C54a 17O19 1273.6 1247.6 22.1
4 Stargazin A _NTMHATTPV-coW CB,1 7 0 ,0, 1287.6 1288.8 22.4
5 Stargazin JCTaEOn= TTW, C5 4 "17019 1273.6 1275.6 21.8
6 9targa2in TIN9r -cg C3He ,3 0 , 1287.6 1288.6 22.6
7 Stargazin .WnWAvTM-. C,6" ,9 1301.6 1302.7 22.6
8 atargazin ANZIrRTTPVCWU C,,H,1 N1 1Oi 1329.7 1330.7 23.0
9 Stargazin fNtWin3TPV- --COOKe 2 nois 1372.7 1373.6 21.7
10 Stargazin ,ANdAmTTPV , C 1H,,N 20 03a 1342.7 1343.5 21.8
11 Stargazin ,sT31ouTTPVcoo C50H,1 1901 80 1329.7 1331.0 22.7
12 Stargazin aJnUMTITBNRTTW-COo C7 nm 27On 1713.9 1714.4 22.7
13 NEZa J&.MBiUEKZIEWVS. C,,fIaNWUOk 1769.0 1769.9 23.7
14 CRIPP Cow C,,R,0IIOU 1334.7 1335.7 20.5
15 GluR1 I.oUNAG"OL"et CmGJm1NUL 1512.8 1513.7 24.1
16 Stargazin =1*nAUn UTUPR-. C,7,^maV 1826.0 1826.5 19.5
17 maluR7a bAZXXTV5S1ILI.Jgs C,,AHU2atn 1690.9 1692.6 24.0
18 Stargazin A-r.TTPVe, CSGN, 02 0  1362.7 1363.4 21.1
19 41lu1 AG. IlNAICJ1aT'G-cons Cesonuo 1 , 1545.2 1545.2 26.1
20 CRIPT .tDTxNZEQT8V_, C61H,1N 16O2 1416.7 1417.7 22.2
Table 2.2. Peptides synthesized and characterized, numbered 1 through 20. a Native
methionine residues were replaced by norleucine (Nle), nF = p-nitrophenylalanine, C =
Dap(4-DMAP), p = Dab(4-DMAP), y = Orn(4-DMAP), the NRR sequence was added on the
N-terminus of peptides to improve solubility at high concentrations, as low solubility of the
probe can lead to high background fluorescence signal due to aggregation. b Masses were
determined by MALDI-TOF spectroscopy. * Retention time from analytical reverse phase
HPLC (YMC C18, ODS-A 5/120, 250x4.6 mm) using a standard gradient (5% acetonitrile
containing 0.1% TFA for 5 min followed by 5-95% acetonitrile containing 0.1% TFA over 35
min in water containing 0.1% TFA at a flow rate of 1 mL/min).
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2-2. Design and Expression of Protein Constructs'
The target proteins of the first study are PSD-95 and Shank3, which contain class I PDZ
domains. In order to facilitate the development of probes for these PDZ domains, each was
cloned as a recombinant GST-fusion protein, shown schematically in Figure 2.3. In addition,
SAP102 and SAP97 PDZ domains (which share a high sequence homology with PSD95 PDZ
domains and can accommodate the same ligands)" and class II PDZ domains from PICKI
and GRIPI were cloned as recombinant GST-fusion constructs. Residues flanking the PDZ
domains were incorporated into these constructs, in order to ensure proper folding of the
isolated PDZ domains.
PSD-95
SAP-102
SAP-97
Shank3
GRIP-1
PICK-1
4
Figure 2.3. Recombinant PDZ domains. PDZ domain-containing proteins used in this study
and common GST-fusion construct for the expressed domains.
Studies have shown that tandem PDZ domains (closely grouped pairs of PDZ domains)
structurally and functionally affect one another. For example, both GRIP 1 PDZ 1 and PDZ5
require the presence of neighboring domains (PDZ2 and PDZ4, respectively) to fold properly
and bind to target ligands.' 5 ' 7 Interactions have been observed, to a lesser extent, between
..............   ........................
................ -
PDZ1 and PDZ2 of PSD-95.' 8 For this reason, tandem domains were cloned together in order
to preserve their native structure and avoid artifacts due to improper folding of artificially
isolated domains.
2-3. Overall Screening Strategy and Validation of Probes'
A two-pronged screening approach to identify optimal fluorescent probes for class I
PSD-95 and Shank3 PDZ domains was developed. In the first phase, a library of peptides
derived from the C-terminal sequence of Stargazin and incorporating the 4-DMAP
fluorophore (Table 2.2) was screened. Stargazin, an auxiliary sub-unit of a±-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, was chosen for its capacity
to interact with the three domains of PSD-95.' 9 Furthermore, given the general promiscuity of
PDZ domains, it was anticipated that a library incorporating the consensus motif T-X-V
would also enable screening for other class I PDZ domains such as Shank3. The terminal ten
residues of Stargazin were chosen in order to best preserve native specificity. Optimal
fluorophore positioning was assessed in a step-wise process, where native residues were first
replaced with 4-DMAP-derived amino acids (except for positions 0 and (-)2, which are
essential for canonical binding) and evaluated for fluorescence increases. In the second
iteration, the fluorescence increase was further optimized by adjusting the length of the
diamino acid linker bearing 4-DMAP in the most sensitive positions (Dap, n=l; Dab, n=2 or
Orn, n=3). Of note, the 4-DMAP fluorophore was initially chosen for its minimal size and the
ease of synthesis of a peptide library by on-resin derivatization; hence, at this stage other
environment-sensitive fluorophores, 6-DMN and 4-DMN, were also tested at the optimal
position with similar and shorter linkers to compensate for ring extension, albeit with lower
relative fluorescence increases (data not shown). This may be due to the fact that these
fluorophores are too large to be accommodated, even though they show some enhanced
properties relative to the 4-DMAP chromophore including maximum fluorescence increase
and stability. These results with the various environment-sensitive fluorophores highlight the
need for the screening approach developed here.
The peptide library was screened for ability to report binding, which was evaluated by
ratiometric analysis of 4-DMAP fluorescence emission intensities in the absence and presence
of the target PDZ domains (see equation (1) and Figure 2.4 for clarification). PSD95-12/3
and Shank3 PDZ domain were tested, and Table 2.3 shows the results of the screen for each
of these proteins.
Ibound (Amax bound
Ifree( Amax bound)
The maximum relative fluorescence increase for all PDZ constructs was obtained for peptide
6; thus, the optimal position and linker length are -5 and Dab (n=2), respectively. This probe
was particularly sensitive to PSD95-3; more than an eighty-fold increase in emission intensity
was observed. Interestingly, similar overall results to PSD-95 were obtained with other
MAGUK PDZ domains, which share a high sequence homology with PSD95-12/3 (SAP102-
12/3 and SAP97-12/3, Figure 2.5) and can accommodate the same ligands.7' 14 This suggests
that MAGUK PDZ domains share common structural features that can be sensed by the
probes. Peptide 6 was also sensitive to the Shank3 PDZ domain, another class I PDZ domain,
as shown in Figure 2.6. A comparison of Figure 2.6 with the top portion of Figure 2.5
demonstrates that the fluorescence increases for the single PDZ domain of Shank3 are lower
in general than those of the single PDZ3 of the MAGUK proteins, most likely because
Stargazin is not the optimal ligand sequence for this particular class I domain. This factor will
be taken into account in the second step of the screening process.
Control experiments were employed to further validate the screening approach. As
expected, no significant fluorescence increase was observed for the Stargazin peptides with
class II PDZ domains from PICKI and GRIPI (Figure 2.7). This confirmed that the probe
binding is driven by specific PDZ domain-cognate ligand interactions. Next, the relative
fluorescence increase was measured for full-length PSD-95 and compared to its constituent
PDZ domains, PSD95-12 and PSD95-3 using peptide 6 (data not shown). The similarity of
the fluorescence output for the native protein and the domain constructs indicated the
relevance of the results obtained with isolated domains and validated the screening approach.
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Figure 2.4. Definition of relative fluorescence increase (RFI). (A) Example of fluorescence
increase obtained with peptide 12. Red line: peptide 12 in PBS (2 [M); green line: peptide 12
in PBS (2 [M) + PSD95-3 (20 [M). The relative fluorescence increase is defined by the ratio
given in equation (1), where the fluorescence intensities Ibound and free are obtained by
averaging at least three independent measurements and are calculated over a range of 5 nm
centered around Xmax boun-
# Peptide Sequence PSD95-3 PSD95-12 Shank3
1 AcTNUTav 1.9 2.5 1.0
2 AC.NaUaTW._. 6.6 3.4 1.1
3 ACNTRaTTPWC 1.7 1.5 1.0
4 ACY2at TV._, 8.0 1.5 1.5
5 ,]NTANaRTTW, 36.1 1.8 2.0
6 CNTaN pVRTTW.. 89.5 3.9 26.7
7 AWMIyRTW. 37.6 2.6 3.0
8 _Asm6RRTT1W.., 19.8 1.9 1.2
9 .WETiMRTTW. 28.7 1.7 1.3
10 ANfANRTTEWC 25.6 1.9 1.3
11 -1ATannuTTW. 17.4 2.0 1.3
Table 2.3. Fluorescence increases of the C-terminal Stargazin-derived peptide
PSD-95 and Shank3 PDZ domains. a = Dap(4-DMAP), s = Dab(4-DMAP), y
= Orn(4-DMAP).
library with
.......... . ............................... .  ...     . ... . 
PSD95-3, SAP97-3, and SAP102-3 Screening Results
100
90 -
80 -
70 -
60 -
50 -
40 -
30 -
20 -
10 -
0
* PSD95-3
* SAP97-3
o SAP102-3
12 13 14 15 16 171 2 3 4 5
liii",I
6 7 8 9 10 11
Peptide number
-.I] -
PSD95-12, SAP97-12, and SAP102-12 Screening Results
12
screen 1 screen 2
10 -1
8 -
M PSD95-12
".6 M SAP97-12
0 SAP102-12
4
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Peptide number
Figure 2.5. PSD-95, SAP-97, and SAP-102 screen results. Top: relative fluorescence
increases (RFI) with the third PDZ domain of PSD-95 and related SAP-97 and SAP-102
proteins. Bottom: relative fluorescence increases (RFI) with the first and second PDZ domains
of PSD-95 and related SAP-97 and SAP-102 proteins.
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Figure 2.7. Relative fluorescence increases (RFI) with the PICKI and GRIP45 PDZ
domains.
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In the second step of the design process, the goal was to generate probes with
improved signaling properties by addressing the affinity and specificity of the ligands for each
domain. Therefore, C-terminal sequences of CRIPT,14'20 NR2a, 4 and GluR1,' known binders
for PSD95-3, PSD95-12, and Shank, respectively, were selected as ligands for the second
series of probes. The series also included negative controls such as a class II ligand, derived
from mGluR7a, and a Stargazin sequence in which critical residues were replaced by Arg
(residues 0 and (-)2). Applying the results of the library screen, the 4-DMAP fluorophore was
appended to a Dab residue at the (-)5 position, and probes were tested with each construct.
The Asn-Arg-Arg (NRR) sequence was appended to each of the peptides used in the second
screen, in order to aid in overall solubility. The affinities of the new sensors were obtained by
fluorescence-based titrations and are reported in Table 2.4, together with relative fluorescence
increases. The studies reveal that 12 and 14 are the best probes for PSD95-3, 13 for PSD95-
12, and 15 for Shank3. Remarkably, probe 15 exhibited a 265-fold fluorescence increase with
the Shank3 PDZ domain. Control sequences, 16 and 17, exhibited negligible fluorescence
increases (and poor affinities when measured) for the targeted domains, thus confirming class
specificity of the probes. Figures 2.5, 2.6, and 2.7 summarize the results from both the first
and second screening processes.
# Origin Peptid. Sequence PSD95-3 PSD95-12 Shank3
(pa arM k (P) M RD (pa aRI
12 Stargazin sm3WNIT1PVW= 0.57*0.23 62.6 5.99*0.76 6.9 10.00*2.44 27.6
13 N2a ,.iNRUUAPSIUSDV= 1.66*0.18 35.1 1.50*0.26 8.6 23.10*0.68 4.9
14 CRIPT -DENcMOTY.w 1.21*0.20 48.8 9.63*1.34 4.5 12.40*4.30 21.0
15 GluRi j MUIGAPjGATGL..O 89.5*20.6 4.6 20.45*3.17 2.0 0.17*0.02 265.0
16 Control tMUWaMPTjMRP. >>50 1.4 n.d. 1.7 n.d. 1.5
17 iGluR7a ,-AM= VISpNI.VI n.d. 2.7 n.d. 1.7 n.d. 1.9
Table 2.4. Binding constants and fluorescence increases for peptides with the optimally
positioned 4-DMAP fluorophore. P = Dab(4-DMAP), X = Norleucine (replaces Methionine in
native sequence), NRR- added to improve solubility, n.d. = not determined.
Together, these results indicate that the selectivity of the native sequences was
preserved after insertion of the fluorophore. Furthermore, for each domain, KD values of
ligands identically derived with 4-DMAP (both position and linker) correlated with relative
. .......... .. . ............................. . .
fluorescence increases when screened under the same conditions. Next, competition
experiments with non-fluorescent peptides were carried out on probes 12 and 15 with their
respective targeted PDZ domains. As shown in Figure 2.8, gradual displacement of probe 12
from PSD95-3 by a non-fluorescent peptide derived from Stargazin can be readily observed
by decrease of the fluorescence signal (similar results were obtained with the Shank3 probe
peptide 15). Affinity constants of the unlabeled peptides could be calculated from these
competitive titrations, showing a stronger global affinity of the labeled peptides. While further
demonstrating the reversibility and specificity of the fluorescent probe-PDZ domain
interactions, these experiments also illustrate the potential of these tools for the screening of
high affinity ligands for target PDZ domains.
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Figure 2.8. Representative competition titration. Unlabeled Stargazin peptide vs. probe 12 /
PSD95-3 complex. Main graph: Fluorescence emission spectra of a 5 [IM solution of peptide
12 and PSD95-3 after sequential additions of 0 (1) to 200 eq. (2) of the non-fluorescent
peptide; (3) 5 tM solution of peptide 12. Insert: Relative fluorescence increases at
corresponding concentrations of unlabeled competing peptide (data, fit, and Kj).
Finally, the binding affinities were also independently evaluated by using a non-
fluorescence-based method, isothermal titration calorimetry (ITC, see Figure 2.9 for
representative data). In this case, the aims were to validate the fluorescence-based results and
also to determine the potential influence of the fluorophore on the probe affinity. The binding
constant of peptide 12 for PSD95-3, determined by ITC, was similar to that obtained by
fluorescence titration, while the dissociation constants of non-fluorescent peptides derived
.. ..............
from CRIPT and Stargazin were in agreement with reported data (Table 2.5). Overall, these
results confirmed the method and revealed an improved affinity of peptide 12 in comparison
to the native peptide sequence.
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27.6
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26.8
Figure 2.9. ITC thermogramr
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Time (min)
. Peptide 12 versus PSD95-3.
# Origin PSD95-3 % (px) No (N)
RFI by ITC from lita
12 Stargain wAnITAN$TTPV~c=N, 0.59*0.60 -
18 Stargazin 4NTAMRRTTPV-coon 7.49*1.07 7-15
19 CRIPT Ac$DTENQOTSV.co 3.44*0.50 3.39
Table 2.5. Summary of ITC control results and comparison with literature values.
aFluorescence polarization values for Stargazin 9
- and CRIPT-derived peptides.
The affinity improvement was attributed to interactions of the fluorophore with a non-
polar patch of the domains that, when combined with the other ligand interactions, translates
into high fluorescence increases and stronger affinities. However, attempts at correlating these
results with structural information did not allow identification of obvious shared elements for
the three sets of domains that would account for the observed response from the 4-DMAP
chromophore at the (-)5 position. By considering the X-ray crystallographic structure of
0 140 160 180
.... ... 
PSD95-3 complexed with a ligand (PDB entry 1TP5) as a starting point and modeling the C-
terminal 6 residues of probe 12, the regions accessible by 4-DMAP on the PDZ domain
surface could be defined, as illustrated in Figure 2.10.
Figure 2.10. Structural modeling of PSD-95 PDZ3
fluorogenic peptide. Red = negative, white = hydrophobic,
electrostatic potential map and
blue = positive.
Surprisingly, the fluorophore is located at the edge of the PDZ domain binding groove
and does not seem to be in the vicinity of any clearly defined hydrophobic patch. In this
context, it is worth noting that another PSD95-3 structure complexed with a 9-residue long
CRIPT peptide' (PDB entry 1BE9) failed to show sufficient electron density to resolve the
location of the ligand (-)5 Tyr residue, thus stressing the lack of a predefined strong
interaction of the PDZ domain with an aromatic ligand residue at this position. Overall, these
structural considerations underscore the importance and efficiency of the general screening
approach that is presented in the design of environment-sensitive probes for interaction
domains such as PDZ domains that do not allow for a rational ligand residue replacement
strategy.
. ..... ..... . ... . . -
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Conclusions
A systematic library approach to the design of fluorogenic peptide-based probes for
PDZ domains has been developed and successfully applied to the generation of probes. This
method can be applied to other classes of domains and can be readily implemented for the
screening of sensors as well as high affinity competing ligands. The new probes exhibit large
fluorescence increases while conserving native sequence specificity. Thus, the probes
constitute valuable tools for in vitro studies of PDZ domain-mediated interactions by enabling
a direct readout of binding. These probes have been further evolved and extended to the study
of other PDZ domains both in vitro and in vivo, which will be discussed in later chapters of
this thesis.
Experimental Methods
Peptide Synthesis (SPPS), Fluorophore Synthesis, and Fluorophore Insertion. Peptides
were obtained either manually or with an automated synthesizer (Advanced ChemTech
automated synthesizer model 396 0) by using standard Fmoc-based solid phase peptide
synthesis procedures. Typically manual synthesis was performed on a 0.02 to 0.04 mmol scale
with Fmoc-Val/Leu/Ile-NovaSyn@ TGT resin (0.2 mmol/g) or Fmoc-PAL-PEG-PS resin (0.2
mmol/g), using standard Fmoc-protected amino acid (6 equivalents), HBTU/HOBt as
coupling reagents (6 equivalents each), and DIPEA (12 equivalents) in DMF or NMP.
Coupling steps were conducted with a 50 mM solution of amino acid (1 mL per 100 mg of
resin) for 1 hour. Fmoc group removal was performed with a 20% solution of 4-methyl-
piperidine in DMF (vol/vol) for 3 x 5 minutes. After removal of the N-terminal Fmoc group,
the resulting free amine was capped with an acetyl group by using an acetic
anhydride/pyridine solution (0.15 M each in DMF).
Peptides incorporating the 4-DMAP environment-sensitive fluorophore were
synthesized using the on-resin derivatization approach previously reported.24 An Alloc-
protected diaminoacid (either Fmoc-Dap(Alloc)-OH, Fmoc-Dab(Alloc)-OH or Fmoc-
Orn(Alloc)-OH from AnaSpec) was initially inserted during the SPPS steps. After capping of
the N-terminal amino group of the peptide sequence, the Alloc-protecting group was
removed. The resin was resuspended in dry dichloromethane (20 mM in peptide) with a
stream of N 2 bubbling through the solution for 5 minutes. Pd(PPh3)4 (0.8 eq.) and
phenylsilane (25 eq.) were then added to the solution, which was maintained under N2
bubbling for another 15 minutes. The resin was then washed with dichloromethane and DMF,
and the degassing/deprotection cycle was repeated two additional times. The resin containing
the free amine was reacted with a solution of the anhydride form of 4-DMAP (4-
dimethylaminophthalenedicarboxilic anhydride, 2 equiv., 50 mM) and DIPEA (4 equiv.) in
NMP. The mixture was allowed to stir overnight. The resin was then washed with DMF and
dichloromethane and ring closure was performed by using a solution of HBTU/HOBt (6
equiv., 50 mM) in NMP or DMF with DIPEA (12 eq.) for 2 hours. The resin was then washed
with DMF and dichloromethane. The coupling/washing cycle was repeated two additional
times in order to achieve full ring closure.
Peptides were deprotected and cleaved from the resin with a TFA/H20/TIPS
(95:2.5:2.5) cleavage cocktail for 2.5 to 3 hours. TFA was evaporated until the peptides
precipitated. The peptides were then triturated and precipitated in cold ether before
purification by reverse phase HPLC on a semi-preparative column (YMC-Pack Pro Ci 8, ODS-
A 5/120, 250x20 mm) in water (0.1% TFA) using an acetonitrile (0.1% TFA) gradient and
monitoring at 228 nm and 350 nm. Peptides were stored lyophilized at -80 0C until use.
Peptide Characterization and Quantification. Peptide identity was confirmed by MALDI-
TOF mass spectroscopy (MALDI-TOF, PerSeptive Biosystems Voyager) using DHB as a
matrix. Purity was assessed by analytical reverse phase HPLC (YMC C18 , ODS-A 5/120,
250x4.6 mm) using a standard gradient (5% acetonitrile containing 0.1% TFA for 5 min
followed by 5-95% acetonitrile containing 0.1% TFA over 35 min in water containing 0.1%
TFA at a flow rate of 1 mL/min). The final peptides were quantified using molar extinction
coefficients of either 4-DMAP (E 4 2 1nm = 6480 M'cm-1 in water) or p-nitrophenylalanine
(E28Onm = 12500 M cm-1).
PDZ Domain Cloning. The cDNA encoding for the genes used for PDZ domain subcloning
were provided by Daniel Choquet (Laboratoire Physiologie Cellulaire de la Synapse; PSD-95,
SAP-102, GRIP-1, PICK-1 and Shank-3) and Morgan Sheng (Picower Institute; SAP-97).
The PDZ domains of interest were cloned into the pGEX-4T-2 vector (GE Healthcare) using
BamHI and XhoI restriction sites. Primers were designed to subclone the PDZ domain(s) as
defined by the ExPASy Proteomics Server (UniProtKB/Swiss-Prot database) plus 5 to 10
extra flanking amino acids on either terminus. The primers also incorporate a TEV cleavage
site between GST and the domain(s) as well as a FLAG tag at the C-terminus. The PCR-
amplified inserts were digested with either BamHI/XhoI or BamHI/EcoRI and ligated into a
BamHI/XhoI- or BamHI/EcoRI-digested pGEX-4T-2 vector.
The first two PDZ domains of PSD-95, PSD95-12 (residues 61 to 249, from
UniProtKB/Swiss-Prot entry P31016), were PCR-amplified using the primers 5'-CGG GAT
CCG AGA ATT TGT ATT TTC AGG GCA TGG AGT ATG AGG AGA TCA CAT TGG
and 5'-CCG CTC GAG TTA CTT ATC GTC ATC GTC TTT GTA GTC GGC ATT GCT
GGG CTT GGC CAC CTT T.
The third PDZ domain of PSD-95, PSD95-3 (residues 302 to 402, from
UniProtKB/Swiss-Prot entry P31016), was PCR-amplified using the primers 5'-CGG GAT
CCG AGA ATT TGT ATT TTC AGG GCC TGG GGG AGG AAG ACA TTC CCC GGG
and 5'-CCG CTC GAG TTA CTT ATC GTC ATC GTC TTT GTA GTC GGC CTC GAA
TCG ACT ATA CTC TTC T.
The first two PDZ domains of SAP-102, SAP102-12 (residues 139 to 338, from
UniProtKB/Swiss-Prot entry Q62936), were PCR-amplified using the primers 5'-CGG GAT
CCG AGA ACC TGT ACT TCC AGG GCA ATG GCA GTG ATG GCA TGT TCA AGT
and 5'-CCG GAA TTC TTA CTT GTC GTC ATC GTC CTT GTA GTC CAT GTC GTT
GAG GTG GAG ACT GCC.
The third PDZ domain of SAP-102, SAP102-3 (residues 393 to 493, from
UniProtKB/Swiss-Prot entry Q62936), was PCR-amplified using the primers 5'-CGG GAT
CCG AGA ACC TGT ACT TCC AGG GC CTG GCT GAG GAA GAC TTT ACC A and 5'-
CCG GAA TTC TTA CTT GTC GTC ATC GTC CTT GTA GTC GGA TTC AAA GCG
ACT GTA CTC.
The 4th and 5th PDZ domains of GRIP-1, GRIP1-45 (residues 430 to 663, from
UniProtKB/Swiss-Prot entry P97879), were PCR-amplified using the primers 5'-CGG GAT
CCG AGA ATT TGT ATT TTC AGG GCT CTA CTA GTC CAC GAG GAA CCA TGA
and 5'-CCG CTC GAG TTA CTT ATC GTC ATC GTC TTT GTA GTC CTC TTG CTC
ATC TGA GTT ATC TTC A.
The PDZ domain of Shank-3, Shank3 (residues 635 to 749, from UniProtKB/Swiss-
Prot entry Q9JLU4), was PCR-amplified using the primers 5'-CGG GAT CCG AGA ACC
TGT ACT TCC AGG GCT CAC ACA GTG ATT ATG TCA TTG ATG and 5'-CCG GAA
TTC TTA CTT ATC GTC ATC GTC CTT GTA GTC TGC GCC GAG CAC TAT CCT CCT
CTG G.
For the cloning of the full PSD-95 protein (UniProtKB/Swiss-Prot entry P31016),
PCR-amplified insert was digested with EcoRI/XhoI and ligated into an EcoRI/XhoI-digested
pET24a vector (Novagen), which afforded a C-terminal His6-tag. PCR amplification was
done with the primers 5'-CGG AAT TCA TGG ACT GTC TCT GTA TAG T and 5'-CCG
CTC GAG GAG TCT CTC TCG GGC TGG GAC.
Expression and Purification of PDZ Domain Constructs. E. Coli BL21 codon plusTM (DE3)-
RIL or RP cells were transformed with each of the GST fusion protein expression plasmids.
Cells were amplified in 0.5 L of an auto-inducing medium2 5 (ZYM-5052, see reference for
detailed composition) first at 37 'C for 4 hours followed by 12 hours at 16 0C. Cells were
harvested by centrifugation and the pellet was resuspended in lysis buffer (100 mM EDTA,
10% glycerol, 1% TritonX-100, 1 mg/mL lysozyme in PBS, pH 7.4) containing protease
inhibitor cocktail III (Calbiochem). Cells were lysed by ultrasonication (Branson Sonifier 450
at 50% power with a 40% duty cycle for 4 min at 4 0C). After addition of 1 mL of a 1 mM
solution of DTT in water, the lysate was cleared by centrifugation (15,334 g, 40 minutes, 4
C). The GST-fusion proteins were purified with 5 mL of Glutathione SepharoseTM 4 Fast
Flow (GE Healthcare) by batch-binding. The bound proteins were washed with 20 volumes of
PBS (pH 7.4) and eluted with 2 volumes of a 10 mM Glutathione in 50 mM Tris (pH 8)
solution. Fractions were analyzed by 12% SDS-PAGE followed by Coomassie staining and
Western blotting (anti-FLAG). Fractions containing the protein were pooled and dialyzed
against PBS (pH 7.4). Protein concentrations were measured using either the BCA assay
(Pierce) with BSA as the reference standard or by determining the absorption at 280 nm in 6
M guanidinium chloride. Purified PDZ domains were aliquoted, flash-frozen and stored at -80
'C in PBS (pH 7.4) until use.
Fluorescence Studies. Fluorescence spectra were recorded on a Fluoromax 3 instrument
(Horiba Jobin Yvon) in 1 cm path length quartz cells (100 mL nominal volume from Starna
Cells). All measurements were performed at a constant temperature of 25 'C. Slit widths
were 3 nm for excitation and 6 nm for emission. The 4-DMAP fluorophore was excited at 421
nm and the spectra were recorded between 432 nm and 730 nm (0.5 nm increments and 0.1 s
integration time).
Relative Fluorescence Increases. The fluorescence increase measurements were performed at
25 'C in PBS buffer (pH 7.4) comparing solutions of (1) 2 [tM of 4-DMAP-containing
peptide alone in PBS and (2) 2 iM of 4-DMAP-containing peptide with 20 [tM of PDZ
domain construct in PBS. Blanks consisting of PBS for (1) and PBS with 20 [M of the
corresponding PDZ domain construct for (2) were subtracted from the respective spectra.
Each final spectrum results from the average of 3 different runs. The fluorescence increase for
each series of peptide and PDZ domain(s) was evaluated by comparing the fluorescence
emission intensities of (2) and (1) at the wavelength of maximal emission of (2). Ratios were
calculated over a 5 nm range centered on the wavelength of maximal emission of (2) and the
values were averaged to yield the reported final ratio.
Fluorescence Titrations. For each titration, the peptide concentration was kept constant
(around 1 to 20 tM) and the protein concentration was varied from values lower than or close
to the anticipated KD to saturation of the fluorescence signal increase. A 150 or 130 L
solution in PBS (pH 7.4) [or MES (pH 6.9)] was prepared for each protein concentration.
Dissociation constants were evaluated using SPECFIT/32TM Global Analysis System for
Windows (version 3.0.39) after averaging at least three independent titrations and taking into
account wavelengths from 432 to 730 nm.
Competition Titrations. Competition experiments were conducted on 450 [tL of a PBS (pH
7.4) solution containing 5 tM fluorescent peptide and 5 tM PDZ domain. The non-
fluorescent peptide solution was added sequentially in small volumes to achieve a range of
concentrations from 1 nM to 2 mM. The titrations were done- at least in triplicate and
averaged. The Ki were obtained by fitting the relative fluorescence increase (RFI, obtained as
described above) of the averaged spectrum to the logarithm of the non-fluorescent peptide
concentration (Log[nFP], Molar) using the Competitive Binding: One Site model from
GraphPad Prism 5 software with the equations (2) and (3):
log(EC50) = log 101og(K;)(I + (2)
maxRFI minRFIRFI = minRFI 1 + o(Iog[nFPI-log(EC50))
where [FP] is the concentration of the fluorescent peptide, KDHuo is the dissociation constant of
the fluorescent peptide with the corresponding PDZ domain (constant, same units as [FP]),
minRI is 1 and maxRH is the RFI in the absence of competitive ligand.
Isothermal Titration Calorimetry. Titrations were conducted on a VP-ITC MicroCalorimeter
(MicroCal). The PDZ domains were dialyzed against PBS buffer (pH 7.4) or MES buffer (pH
6.9). The protein and peptide samples (prepared in the same buffer) were degassed separately
for 10 min under vacuum with stirring. The PDZ domain (20 to 50 tM, 1.8 mL) was loaded
into the sample cell and a 400 to 1000 [tM peptide solution (250 [tL) was drawn into the
syringe. Typically 30 to 50 injections were programmed, with the first injection volume set at
0.5 L (1 s injection) and the remaining at 7 tL (in 45 injections of 14 s each). The spacing
between injections was 240 s. The reference power was 30 tcal/s with an initial delay of 1
minute. Experiments were conducted at 25 'C with a stirring speed of 500 rpm. The raw data
were collected and analyzed by ORIGIN software (MicroCal). Thermodynamic parameters
were determined by non-linear least squares fitting using a One Set of Binding Sites model.
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Chapter 3
Development and Validation of a Novel C-terminal Caging
Strategy for PDZ Domain Ligands
Introduction
Photolabile chemical caging groups are valuable tools to achieve spatiotemporal
control of biological interactions. Molecules of interest can be rendered biologically inert via
modification with a caging group, a photocleavable moiety that acts like a protecting group.
The active species of the molecule is liberated by light-driven unmasking of the critical
functional group, allowing the active species to bind its intended target in the biological
pathway of interest.' The application of caged molecules allows for temporal control in the
study of dynamic biological events that cannot be fully addressed with conventional genetic
or immunological approaches. Caging strategies have been successfully used for many
biological applications, including the masking of neurotransmitters and of key phosphorylated
residues in peptide and protein sequences.2
PDZ domains are involved in many critical transient interactions that contribute to the
assembly and localization of macromolecular complexes in signal transduction pathways.3 In
chapter 2 the design and development of fluorescence-based probes to detect PDZ domain-
mediated interactions was discussed. Toward the goal of gaining additional chemical
approaches for studying the various modes of PDZ domain regulation in vivo, the utility of the
probes was extended through the pursuit of functionally caged variants. A successful caging
strategy would render PDZ domain ligands efficacious in probing the spatiotemporal
dynamics of the complex protein-protein interactions involving these ligands. In this chapter
studies toward the development and validation of caging strategies to control the function and
interactions of PDZ domains in vitro will be presented.
Results and Discussion
3-1. C-terminal caging strategy
We developed an approach to investigate PDZ domain-mediated interactions similar
to the approach taken to study the role of phosphorylation in protein-protein interactions via
caging of peptides.4 ' For example. in protein phosphorylation studies, the phosphorylated
residues are critical components for binding to proteins in signaling networks, and the
masking of these essential binding determinants can hinder binding. In a similar manner, the
binding of PDZ domains to their cognate ligands also relies upon the presence of an essential
binding determinant; in this case, it is the C-terminal carboxyl group of the PDZ domain
ligand. In light of these similarities, a strategy based on caging of the critical C-terminal
carboxyl of the peptide-based ligand was pursued. Caging of the C-terminal carboxyl should
allow for temporal control of binding to a cognate PDZ domain, since this moiety is essential
for binding. Figure 3.1 depicts the residue contacts that can be formed between a PDZ
domain and its partner ligand only in the absence of a C-terminal caging group. In these
studies, the advantageous properties of environment sensitive probes provided an excellent
tool for studying the efficiency and utility of this strategy. Chapter 2 of this thesis discusses
the utility of these tools to directly trigger release of and report binding of peptide-based
ligands with cognate PDZ domains. Therefore, the caged ligands were designed as an
extension of the fluorogenic probes discussed in Chapter 2.
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Figure 3.1. Schematic of control of PDZ domain binding by caging of the ligand's critical C-
terminal acid. A) release of caging group (red) from fluorogenic ligand. B) Example of
residue contacts between PDZ ligand (green) and PDZ domain binding groove (black), which
can be formed only after uncaging. Note that the C-terminal cage (red) should obliterate
binding due to steric hindrance and interference with the hydrogen bond contacts that are
normally made by the C-terminal ligand acid.
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3-2. Design and synthesis of caged C-terminal ligands
Structural studies have shown that the canonical binding of PDZ domain ligands
essentially involves C-terminal motifs of target proteins, typically through conserved
interactions with the hydrophobic side chain and carboxylate group of the terminal amino acid
as well as with the side chain of the residue in the (-)2 position (see Figure 3. 1B). The nature
of the residue at the (-)2 position differs from one domain to another, and as such is
commonly used to distinguish domains into classes.6 Given the universal essentiality and
intrinsic chemical characteristics of the C-terminal carboxylate group, this functional group
was selected for caging. Addition of a photolabile group at this position would both abolish
key hydrogen-bonding interactions that are critical in binding to the domains, and introduce
steric hindrance from the caging group itself. This caging strategy should therefore prevent,
or significantly reduce, interactions with cognate PDZ domains.
The 1-(2-nitrophenyl)ethyl (NPE) cage has been utilized successfully to cage
phosphate moieties of peptides4'5 and many other biologically relevant functional groups, due
to the relative ease of synthesis of NPE derivatives, as well as the stability and favorable
uncaging properties of this molecule.' Therefore, focus was placed on incorporating the NPE
cage into the PDZ ligands. The general synthetic strategy used to obtain ligands caged at
their C-terminal carboxylic acid consisted of introducing the photolabile group after solid
phase peptide synthesis, by relying upon activation of the caging group rather than the C-
terminal carboxylate moiety. This strategy avoids the potential for racemization of the
terminal amino acid. Fluorogenic peptides were first synthesized by standard Fmoc-based
SPPS methods on TGT resin, which includes a mildly acid sensitive linker, to yield peptide 1
(see Scheme 3.1), as described in Chapter 2. The resulting peptides were cleaved from the
resin with 0.5% TFA, preserving the side-chain protecting groups in order to allow for
selective coupling of the activated caging group. Concentration in vacuo afforded peptide 2
for subsequent caging.
Scheme 3.1. Synthesis of free acid fluorogenic peptide 2 for caging.
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Activation of the NPE caging group was necessary for coupling to the C-terminal acid
(see Scheme 3.2). Toward this end, 2-nitroacetophenone, 3, was converted to the
corresponding hydrazone, 4, by reaction with hydrazine monohydrate and glacial acetic acid
in ethanol. Hydrazone 4 was then oxidized with MnO 2 to yield 1-(2-nitrophenyl)diazoethane,
5, which upon reaction with 2 yielded peptide 6. The desired caged fluorogenic peptide 7 was
obtained after standard TFA-based deprotection of side-chain protecting groups and HPLC
purification. Products were confirmed by analytical HPLC and ESI-MS analysis.
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Scheme 3.2. Synthesis of NPE-caged probe 7.
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In this study, we chose to use the probe sequences derived from the two synaptic
proteins Stargazin and GluRI, which were optimized for binding to PSD-95 and Shank3 PDZ
domains, respectively, as described in the work presented in Chapter 2. For the purpose of
this study, these two PDZ domains function as representative class I PDZ domains with which
to investigate the new caging strategy.
The Stargazin and GluR1-5b caged probes (8 and 10) are shown in Table 3.1 below,
along with details on the characterization by ESI-MS. It should be noted that the caging
group is susceptible to cleavage during matrix-assisted laser desorption/ionization time-of-
flight (MALDI-TOF) laser desorption, which is why ESI-MS was used for mass
characterization. Table 3.1 also shows the characterization of non-caged probes 9 and 11 (i.e.
probes that were never caged).
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8 Stargazin A.NTAN#RTTPW,, CR,3 NI802n 31.8 1438.5 1438.9*
9 Stargazin e.NTANORTTVWoa s C558 6N1 70 19  23.9 1289.4 1288.6
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Table 3.1. Characterization of caged fluorogenic probes and their parent noncaged peptides.
a p = Dab(4-DMAP). b tR = retention time. Purity was assessed by analytical reverse phase
HPLC using a standard gradient (5% acetonitrile containing 0.1% TFA for 5 minutes
followed by 5-95% acetonitrile containing 0.1% TFA over 50 minutes in water containing
0.1% TFA at a flow rate of 1 mL / min). All peptides were more than 95% pure as judged by
analytical HPLC. ' The peptide-based ligand identity was either confirmed by MALDI-TOF
analysis or by ESI-MS. (*) = ESI-MS, 1+ peak. (**) = ESI-MS, 2+ peak.
3-3. Validation of caging strategy in vitro
In the first phase of studies, the caging and subsequent uncaging of the C-terminal acid
of probes 8 and 10 was validated qualitatively by relative fluorescence increase comparisons.
The environment-sensitive fluorophore in these ligands yields a significant fluorescence
increase upon binding to partner PDZ domains, which allows for the use of fluorescence
spectroscopy to visualize binding after uncaging both qualitatively and quantitatively. The
relative fluorescence increases of caged and uncaged peptides in the presence and absence of
cognate PDZ domains were evaluated, and compared with fluorescence increases of non-
caged ligands, as shown in Figure 3.2. Introduction of the NPE cage clearly resulted in
significant loss of fluorescence increase upon addition of the cognate domain, yielding
fluorescence increases lower than 11% of that of the non-caged peptides (Figure 3.2, t = 0 s).
Caged peptide 10 displays a mere 5% of the fluorescence signal of its parent non-caged
peptide. This observation also reflects a lower binding affinity of the caged ligands, as
previously a correlation has been shown between fluorescence increase and affinity within a
given series of ligands for the same PDZ domain. Therefore, the caged fluorescent ligands do
not bind appreciably to their partner PDZ domains. Additionally, the fluorescence of each
caged ligand alone was compared with the fluorescence emission of uncaged ligand alone
irradiated for 300 seconds on a transilluminator, the longest duration of irradiation utilized in
..... ..... ... .... ........ .
the in vitro studies. The emission from both species is the same, demonstrating that the
process of uncaging does not lead to an artificial increase in the fluorescence signal of the
environment-sensitive fluorophore.
Exposure of the caged ligands to various durations of UV-irradiation (Figure 3.2, t =
120 s and 300 s) in the presence of the scavenger 1,4-dithiothreitol (DTT) and cognate PDZ
domain resulted in stepwise recovery of the fluorescence signal. Due to the release of nitroso
acetophenone upon uncaging of the NPE group, the irradiation in vitro is carried out in the
presence of DTT, which reacts irreversibly with the by-product and prevents unwanted side
reactions. Application in vivo does not require supplementation with DTT, since the
scavenger glutathione is present in ample amounts in cells. The NPE caging group is released
with 350 nm light; previous in vivo studies have shown the efficient release of an NPE caging
group from a phosphorylated amino acid after only 100 ms irradiation with an Argon ion laser
(333.6-363.8 nm range). 7 The transilluminator is much less powerful than a laser, and
therefore longer irradiation times are necessary to mimic laser-mediated release in these in
vitro studies. This translates to the partial release of the caging group by photolysis, followed
by binding of ligand to PDZ domain. At t = 300 s, as seen in Figure 3.2, probe 8 yields a
fluorescence increase of 70% of the maximum possible 89-fold increase in the presence of
PSD-95 PDZ3. Uncaging for t = 300s of the GluR1-5b ligand yields a fluorescence increase
of 66% of the maximum 265-fold (see Chapter 2 for relative fluorescence increases).
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Figure 3.2. Qualitative validation of caged PDZ
(top) PSD-95 PDZ3 and (bottom) Shank3PDZ.
domain + ligand images.
domain ligands. Probes in the presence of
PDB entry 1BE9 used for sample PDZ
Initial investigations demonstrated that recovery of viable uncaged ligand plateaus at about t =
300 s uncaging, hence this was used as the maximum uncaging time (data not shown). The
application of this technology should be transferable to studies in cellulo, as the
corresponding time of uncaging by laser is a reasonable duration of irradiation that should not
damage cells. Figure 3.3 shows the HPLC timecourse of uncaging; caged peptide, uncaged
peptide, and uncharacterized by-product are observed.
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Figure 3.3. HPLC timecourse of Stargazin probe uncaging. Top: overlay of HPLC traces
from different timepoints; legend indicates length in seconds of irradiation for each timepoint.
Bottom: bar graph representation of caged peptide, uncaged peptide, and by-product observed
at various timepoints of irradiation.
As shown in Figure 3.3, about 18% of the final product observed after irradiation for
300 s is composed of caged peptide and an unidentified by-product. Most likely, the by-
product is the result of one or more modes of fluorophore degradation under the irradiation
conditions. However, overall a significant recovery of viable ligand and its subsequent
interaction with partner PDZ domain is observed upon uncaging, validating this caging
approach for PDZ domain ligands.
To more quantitatively validate this method, the binding affinities of the caged
peptides were evaluated by fluorescence titrations. Caged probe 8 binds PSD-95 with a weak
affinity (KD approximation of 34.9 [M), as compared with the KD of 0.57 [tM for the parent
non-caged ligand, a 60-fold difference. The binding constant between a non-fluorescent
. ............
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Stargazin peptide and PSD-95 is 7-15 [tM,8 hence the caged compound would not be able to
out-compete the natural binding event in vivo. Caged probe 10 is also a weak binder for
Shank3 PDZ relative to the dissociation constant of the parent uncaged peptide. Titration
studies yield a KD of greater than 11.4 [tM. This lower bound estimate for the dissociation
constant is 67-fold higher than the KD of the parent non-caged ligand (0.17 riM). The large
differences in caged versus non-caged probe affinities clearly demonstrate the efficiency of
masking the C-terminal carboxylate residue to prevent interaction of PDZ domain ligands
with cognate domains.
Overall, we have shown with two different PDZ domain ligand / PDZ domain protein
pairs that NPE-caging of the C-terminal acid effectively decreases binding affinity, and that
binding can be controlled by releasing the caging group with UV light. A significant recovery
of viable uncaged product is observed upon uncaging. Future studies will be focused on
optimizing this strategy for cellular imaging applications. In particular, various caging groups
will be evaluated. Many different small-molecule caging groups have been reported, each
with varying photophysical properties. One potential avenue to explore is the incorporation
of a cage that is susceptible to two-photon uncaging, which is often advantageous for in vivo
studies, since two photons of long wavelength infrared light are absorbed sequentially, rather
than one photon of ultraviolet light. Two-photon uncaging offers excellent spatial control in
photoactivation,9 and has been particularly useful in neuronal studies.''
Conclusions
We have developed a synthetic strategy for caging the carboxyl group of the C-
terminal amino acid of peptides. This caging application has not yet been reported in the
literature. Since most PDZ domain ligands rely upon their C-terminal carboxyl moiety for
binding to partner domains, they are perfect candidates for this caging approach. We have
shown that the introduction of the NPE cage at the C-terminus of fluorogenic Stargazin and
GluR1 probes successfully inhibits binding of these ligands to PSD-95 PDZ3 and Shank3
PDZ, respectively. Upon uncaging with UV light, we recover significant amounts of the
uncaged ligands, whose fluorophores report binding to cognate PDZ domains. This strategy
is general for PDZ domains, and should be applicable to all domains of this family.
This new strategy allows for the spatial and temporal control of binding events
mediated by the peptide C-terminal carboxyl group, and could be extended to the full protein
ligands. Additionally, we are particularly interested in the application of caged PDZ domain
ligands in neuronal studies. Specifically, these tools could be used to perturb existing PDZ
domain - ligand interactions at the synapse, allowing for observation of the downstream
effects of this competitive interaction. The environment-sensitive fluorophore in these probes
not only allows for validation of the caging strategy, but also increases the affinity of the
ligand for the cognate PDZ domain, as previously reported. Hence, these caged fluorescent
probes are appropriate for competition studies in neurons. Specifically, by caging the C-
terminus the binding event is controlled, and by rendering the synthetic ligand a better binder
for the PDZ domain, the ability to compete out the natural protein-protein interactions is
effectively enhanced. We envision that, with optimization of imaging equipment, the
environment-sensitive fluorophore within these probes could also be used to directly detect
these binding events upon uncaging. Together, these approaches would allow researchers to
exploit the full potential of the C-terminal caged fluorescent probes.
Experimental Methods
Peptide Synthesis (SPPS), Fluorophore Synthesis, and Fluorophore Insertion.
Peptides were obtained either manually or with an automated synthesizer (Advanced
ChemTech automated synthesizer model 396 Q) by using standard Fmoc-based solid phase
peptide synthesis procedures. Typically manual synthesis was performed on a 0.02 to 0.04
mmol scale with Fmoc-Val/Leu/Ile-NovaSyn@ TGT resin (0.2 mmol/g) or Fmoc-PAL-PEG-
PS resin (0.2 mmol/g), using standard Fmoc-protected amino acid (6 equivalents),
HBTU/HOBt as coupling reagents (6 equivalents each) and DIPEA (12 equivalents) in DMF
or NMP. Coupling steps were conducted with a 50 mM solution of amino acid (~1 mL per
100 mg of resin) for 1 hour. Fmoc group removal was performed with a 20% solution of 4-
methyl-piperidine in DMF (vol/vol) for 3 x 5 minutes. After removal of the N-terminal Fmoc
group, the resulting free amine was capped with an acetyl group by using an acetic
anhydride/pyridine solution (0.15 M each in DMF).
Peptides incorporating the 4-DMAP environment-sensitive fluorophore were
synthesized using the on-resin derivatization approach previously reported.' 2 An Alloc-
protected diaminoacid (either Fmoc-Dap(Alloc)-OH, Fmoc-Dab(Alloc)-OH or Fmoc-
Orn(Alloc)-OH from AnaSpec) was initially inserted during the SPPS steps. After capping of
the N-terminal amino group of the peptide sequence, the Alloc-protecting group was
removed. The resin was resuspended in dry dichloromethane (20 mM in peptide) with a
stream of N2 bubbling through the solution for 5 minutes. Pd(PPh3)4 (0.8 eq.) and
phenylsilane (25 eq.) were then added to the solution, which was maintained under N2
bubbling for another 15 minutes. The resin was then washed with dichloromethane and DMF,
and the degassing/deprotection cycle was repeated two additional times. The resin containing
the free amine was reacted with a solution of the anhydride form of 4-DMAP (4-
dimethylaminophthalenedicarboxilic anhydride, 2 equiv., 50 mM) and DIPEA (4 equiv.) in
NMP. The mixture was allowed to stir overnight. The resin was then washed with DMF and
dichloromethane and ring closure was performed by using a solution of HBTU/HOBt (6
equiv., 50 mM) in NMP or DMF with DIPEA (12 eq.) for 2 hours. The resin was then washed
with DMF and dichloromethane. The coupling/washing cycle was repeated two additional
times in order to achieve full ring closure.
Cleavage from the resin by 0.5% TFA in dichloromethane (2.5 hrs) was performed, in
order that the side chain protecting groups would not be affected. The reaction mixture was
dissolved in the minimal volume dichloromethane, followed by addition of a large volume of
hexane. Evaporation of the solvents by rotary evaporator yielded a powder, which was
transferred to two Eppendorf tubes with a minimal volume dichloromethane. 10 eq. Mn(IV)
oxide and 1 eq. 2-nitroacetophenone hydrazone were transferred to separate Eppendorf tubes,
and they were then placed on the shaker for 30 min. The tubes were centrifuged, and then the
solutions were filtered (using about 200 tL dichloromethane) into the tubes containing
peptide. These reaction mixtures were covered with foil and placed on the shaker overnight.
The reaction mixture was concentrated on the SpeedVac.
Final deprotections were carried out with a TFA/H 20/TIPS (95:2.5:2.5) cleavage
cocktail for 2.5 to 3 hours to afford the NPE-caged probe. The peptides were then triturated
and precipitated in cold ether before purification by reverse phase HPLC on a semi-
preparative column (YMC-Pack Pro C18, ODS-A 5/120, 250x20 mm) in water (0.1% TFA)
using an acetonitrile (0.1% TFA) gradient and monitoring at 228 nm and 350 rnm. Peptides
were stored lyophilized at -80 OC until use.
Peptide Characterization and Quantification. Peptide identity was confirmed by ESI-MS.
Purity was assessed by analytical reverse phase HPLC (YMC C18 , ODS-A 5/120, 250x4.6
mm) using a standard gradient (5% acetonitrile containing 0.1% TFA for 5 min followed by
5-95% acetonitrile containing 0.1% TFA over 50 min in water containing 0.1% TFA at a flow
rate of 1 mL/min). The final peptides were quantified using the molar extinction coefficient of
4-DMAP (E421nm= 6480 M'cm1 in water).
Cloning of Shank3 PDZ domain constructs. The third PDZ domain of PSD-95,
PSD95-3 (residues 302 to 402, from UniProtKB/Swiss-Prot entry P31016), was PCR-
amplified using the primers 5'-CGG GAT CCG AGA ATT TGT ATT TTC AGG GCC TGG
GGG AGG AAG ACA TTC CCC GGG and 5'-CCG CTC GAG TTA CTT ATC GTC ATC
GTC TTT GTA GTC GGC CTC GAA TCG ACT ATA CTC TTC T, as described in Chapter
2 of this document. The PCR-amplified inserts were digested with BamHI/XhoI and ligated
into a BamHI/XhoI-digested pGEX-4T-2 vector (GE Healthcare) for GST-TEV-
PSD95PDZ3-FLAG.
The PDZ domain of Shank3 (residues 635 to 749, from UniProtKB/Swiss-Prot entry
Q9JLU4), was PCR-amplified using the primers 5' -CGG GAT CCG AGA ACC TGT ACT
TCC AGG GCT CAC ACA GTG ATT ATG TCA TTG ATG and 5' -CCG GAA TTC TTA
CTT ATC GTC ATC GTC CTT GTA GTC TGC GCC GAG CAC TAT CCT CCT CTG G,
as described in Chapter 2 of this document. The PCR-amplified inserts were digested with
BamHI/EcoRI and ligated into a BamHI/EcoRI-digested pGEX-4T-2 vector (GE Healthcare)
for GST-TEV-Shank3PDZ-FLAG.
Expression and Purification of PDZ Domain Constructs. E. Coli BL21 codon plusTM (DE3)-
RIL or RP cells were transformed with each of the GST fusion protein expression plasmids.
Cells were amplified in 0.5 L of an auto-inducing medium (ZYM-5052, see reference for
detailed composition) first at 37 'C for 4 hours followed by 12 hours at 16 C. Cells were
harvested by centrifugation and the pellet was resuspended in lysis buffer (100 mM EDTA,
10% glycerol, 1% TritonX-100, 1 mg/mL lysozyme in PBS, pH 7.4) containing protease
inhibitor cocktail III (Calbiochem). Cells were lysed by ultrasonication (Branson Sonifier 450
at 50% power with a 40% duty cycle for 4 min at 4 C). After addition of 1 mL of a 1 mM
solution of DTT in water, the lysate was cleared by centrifugation (15,334 g, 40 minutes, 4
C). The GST-fusion proteins were purified with 5 mL of Glutathione SepharoseTM 4 Fast
Flow (GE Healthcare) by batch-binding. The bound proteins were washed with 20 volumes of
PBS (pH 7.4) and eluted with 2 volumes of a 10 mM Glutathione in 50 mM Tris (pH 8)
solution. Fractions were analyzed by 12% SDS-PAGE followed by Coomassie staining and
Western blotting (anti-FLAG). Fractions containing the protein were pooled and dialyzed
against PBS (pH 7.4). Protein concentrations were measured using either the BCA assay
(Pierce) with BSA as the reference standard or by determining the absorption at 280 nm in 6
M guanidinium chloride. Purified PDZ domains were aliquoted, flash-frozen and stored at -80
'C in PBS (pH 7.4) until use.
Fluorescence Studies. Fluorescence spectra were recorded on a Fluoromax 3 instrument
(Horiba Jobin Yvon) in 1 cm path length quartz cells (100 mL nominal volume from Starna
Cells). All measurements were performed at a constant temperature of 25 'C. Slit widths
were 3 nm for excitation and 6 nm for emission. The 4-DMAP fluorophore was excited at 421
nm and the spectra were recorded between 432 nm and 730 nm (0.5 nm increments and 0.1 s
integration time).
Uncaging and Relative Fluorescence Increases. Caged fluorescent ligands were uncaged in
a glass apparatus with a pathlength of 1 mm on a UV transilluminator for 0, 120, and 300
seconds, in the presence of 0 or 20 tM protein and 5 mM 1,4-dithiothreitol. The emission
spectra of the resultant solutions were gathered on a fluorimeter, and the maximum emission
intensities were compared with the emission intensity of the caged compound alone at that
Xmax, yielding the fluorescence increase upon uncaging and binding. These values were
compared with the fluorescence increase of non-caged fluorescent ligand with the partner
PDZ domain.
Fluorescence Titrations. For each titration, the peptide concentration was kept constant (2
tM) and the protein concentration was varied from values lower than or close to the
anticipated KD to saturation of the fluorescence signal increase. A 150 or 130 [tL solution in
PBS (pH 7.4) was prepared for each protein concentration. Dissociation constants were
evaluated using GraphPad Prism 5 software after averaging at least three independent
titrations and taking into account wavelengths from 432 to 730 nm.
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Chapter 4
Application of Chemical Probes to the Study of Shank3
PDZ Domain Dimerization
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Introduction'
The multi-domain protein Shank is a master-scaffold protein found in the postsynaptic
density (PSD) of neurons.2 While multiple different interactions between Shank and other
proteins have been observed and delineated, specific mechanisms that modulate these
interactions in the PSD remain to be elucidated. The PSD comprises a network of
scaffolding, cytoskeletal and signaling proteins. These proteins form complexes that control
the receptors of the postsynaptic membrane, aid in signal transduction, and make up the
structural framework of the PSD, all of which are critical to learning and memory.' 4
Macromolecular assemblies of proteins in the PSD are usually assembled around scaffolding
proteins, one of which is the Shank family. Shank proteins contain multiple putative
interaction domains, including an ankyrin repeat domain, an SH3 domain, a SAM domain, a
proline-rich domain, and a PDZ (PSD-95/DLG/ZO-1) domain.5
PDZ domains are essential protein modules involved in the assembly and localization
of protein-protein complexes, and they function by binding C-terminal sequences of partner
proteins. Critical to Shank are the binding partners Homer and GKAP, which bind to the
proline-rich domain and the PDZ domain of Shank, respectively. Significantly, Homer,
Shank and GKAP form an oligomeric complex that is thought to act as a bridge between the
structural proteins of the postsynaptic cytoskeleton and the receptors at the postsynaptic
membrane as shown in Figure 4. 1A. 6 Many PDZ domain-ligand interactions are promiscuous
and display modest low micromolar affinities, and it is therefore likely that other mechanisms
exert control over these interactions in the PSD. Although high throughput screens have
successfully identified multiple PDZ domain-ligand interactions,7 these studies have not
specifically taken into account higher order interactions that might provide an additional level
of affinity modulation for PDZ domain-ligand interactions. Chemical and biophysical
investigations designed to probe which modes of control are indeed relevant to specific PDZ
domain-ligand interactions would aid in a more complete understanding of the control,
regulation, and mechanisms of these proteins and their complex networks. Experimentally
controlled characterizations of the Shank3 PDZ domain in solution suggest that the formation
of higher-order Shank complexes is critical to the modulation of Shank ligand-binding
affinity, aiding the Shank protein in fulfilling key structural and functional roles in the
neuronal PSD.
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Figure 4.1. Probing the Shank PDZ domain. A) Schematic of macromolecular complexes
that rely on the Shank protein in the PSD. B) Fluorescent probe for Shank3 PDZ domain;
upon binding to the Shank3 PDZ domain, an increase in the emission intensity of the
solvatochromic fluorophore is observed. The previously-reported design and screening
approach for the development of PDZ domain probes yielded this GluRl-based fluorescent
peptide as the optimal probe for the Shank3 PDZ domain.8 k = norleucine; graph shows
fluorescence emission spectra of unbound (purple) and Shank3-bound (orange) states.
Conventionally, PDZ ligand residue numbering begins at 0 for the C-terminal residue and
continues sequentially in the negative direction toward the N-terminus.
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The native Shank protein (Figure 6.2) may oligomerize through a variety of interaction
mechanisms. Shank and Homer form a polymeric network that provides structural and
functional integrity to dendritic spines.2 Shank1 can homodimerize through interactions
between its component ankyrin repeat and SH3 domains,9 and Shank can potentially
multimerize in a tail-to-tail manner due to the homomeric and heteromeric interactions
between SAM domains of different Shank molecules. Many of these oligomerized states of
Shank are believed to be necessary for maintaining overall architecture and function of
synaptic proteins. 0 Previously, the individual PDZ domain of Shanki has been shown to
exist as both a monomer in solution and a dimer in solution and when complexed with peptide
ligand in crystallization studies."' 12 The interdomain contact in the dimer observed in the
Shank1 crystal structure involves an extended @B/3C loop as well as exceptionally long N-
and C- terminal extended p-sheets. These regions of extended secondary structure exhibit
high sequence identity among the Shank PDZ domains, yet vary significantly in sequence and
length in other PDZ domains, including the canonical PSD-95 PDZ3 monomer (see SI Figure
Si)." These structural features may account for the non-canonical dimerization behavior of
the Shank1 PDZ domain, and suggest that the PDZ dimer may be a relevant species across the
entire Shank family.
In light of the ample evidence for the formation of higher-order complexes involving
multiple copies of Shank, synergistic approaches were designed to investigate whether
Shank3 PDZ domain dimerization modulates the affinity of this domain for partner ligands.
An integral component of these studies was the application of fluorescence-based probes (see
Chapter 2) to quantify the functional effect of Shank3 PDZ domain dimerization on ligand
binding capabilities. The design and development of these probes is described in Chapter 2 of
this document.8 Utilizing controlled protein dimerization in solution, in conjunction with the
fluorescent probe that was developed previously for the Shank3 PDZ domain (Figure 4. 1B),
studies were designed to probe whether or not protein oligomerization state is a critical factor
in determining the affinity of this domain for cognate ligands.
Results and Discussion
4-1. Molecular biology and expression of all Shank3 PDZ domain constructs'
Studies to address the functional consequences of Shank3 PDZ domain dimerization
on ligand binding will be presented in this chapter. In order to investigate the functional
significance of Shank3 PDZ domain dimerization, the isolated PDZ domain with flanking
residues was expressed as a fusion construct with multiple different fusion partner domains
(see Figure 4.2). These constructs allow for the controlled study of the PDZ domain itself,
and overcome the obstacles of purifiying and handling the full 1741-residue Shank3 protein in
vitro.
There are three different Shank family proteins, each of which shows a distinct pattern
of expression in different tissues. However, they are similar in domain structure, and their
PDZ domains are highly homologous (see Figure 4.2A), binding to the same C-terminal
ligands. The regions highlighted in red in the Figure 4.2A alignment correspond to the PA
and @F sheets of Shank, and the region in blue is the sB-1C loop, all of which form the dimer
interface in the Shanki PDZ domain crystal structure. These regions display high sequence
homology within the Shank family, but not with the canonical PSD-95 PDZ3.
Q9WV48Shank1_rat
Q9QX74_Shank2_rat
Q9JLU4_Shank3_rat
P31016_DLG4_rat
Q9WV48 Shank1 rat
Q9QX74_Shank2_rat
Q9JLU4_Shank3_rat
P31016 DLG4rat
SGSDTIZZTVIILQKKDSEGFGFVLRGAKAQTPzEEFTPTPAFPALQYLESVDEGGVAW
AASDCXIED TWIQKKDNEGFGFVLRGAXADTPIEEFTPTPAPALQYLESVDEGGVAW
SHSDTVXDDVLZQKRDHEGFGFVLRGARAZTPIEErTPTPAFPALQYLESVDVEGVAW
LGEEDIPREPRRIVIHRGSTGLGFNIVGGEDGE---------GIFISFILAG----GPADL
RAGLARMGDFLIEVNGQNVVKVGHRQVVNMIRQGGMTLUVKVVMVTRHPDMDEAVH
QAGLRTGDFLIEVNNENVVKVGHRQVVNMIRQGGUEZVKVVTVTRNLDPDDTAR
KAGLRTGDFLIEVNGVNVVKVGHKQVVGLIRQGGERLVMKVVSVTRKPEEDSARR
SGELRKGDQILSVNGVDLRNASHEQAAIALKNAGQTVTIIAQYKPEEYSRFEA--
U
JIL
U0
SW*k3
PD100"o~
Figure 4.2. Shank3 PDZ domain constructs. A) Alignment of Shank family PDZ domains.
The Shank3 PDZ domain residues here correspond to those used in the various protein
constructs used. B) Shank3 and schematic of different Shank3PDZ protein constructs.
Flanking residues from the native Shank3 sequence were incorporated around the Shank3
PDZ domain, to ensure proper folding of the domain. In every case except the His6-TEV-
Shank3 construct, which was treated with TEV protease to yield the PDZ domain alone, the
Shank3 PDZ domain and flanking residues are surrounded by the TEV sequence on the N-
terminal end and the His6 tag on the C-terminus. Before the TEV sequence in the GST and Fv
constructs there are a thrombin tag and a three glycine linker, respectively. Original
experiments were done using the GST-Shank3PDZ-FLAG construct. Fluorescence titrations
and control experiments were repeated with a GST-Shank3PDZ-His6 construct, and all were
in agreement with the previously obtained results. Hence, the identity of the C-terminal tag
does not affect the behavior of the GST construct. Note that the ITC results presented in the
main text were obtained from the GST-Shank3PDZ-FLAG construct, and all other results
presented herein are from the GST-Shank3PDZ-His6 construct.
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All of the constructs extend well beyond the residues necessary for PDZ domain
dimerization, yet the Shank3 PDZ domain alone is not sufficient for dimerization in solution,
as determined by size exclusion chromatography (Figures 4.3 and 4.4). Glutathione S-
transferase (GST) and IgG-binding domain BI of Streptococcal protein G (GB1) fusions
afforded obligate dimeric and monomeric Shank3 PDZ domain constructs, respectively. A
complementary approach utilizing the Fv (optimized FKBP) domain allowed for external
regulation through a chemical inducer of dimerization (CID, AP20187); 3' 14 Without
AP20187 (abbreviated AP) the Fv construct is a monomer, but in the presence of AP the
construct is a dimer.
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Figure 4.3. Size exclusion chromatography results for protein constructs. These results
establish that GB1-Shank3PDZ and Fv-Shank3PDZ are monomeric, while GST-Shank3PDZ
and Fv-Shank3PDZ+AP are dimeric. Molecular weights were calculated based on elution
volume and comparison with size standards Albumin (66,000 Da), Ovalbumin (43,000 Da),
and Ribonuclease A (13,700 Da). Y-axis normalized to the largest peak.
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Figure 4.4. Size exclusion chromatography results for Shank3 PDZ domain alone, with and
without His6 tag. These results confirm that the Shank3 PDZ domain with only a His6 tag and
without any tags is monomeric (i.e. the tags in the constructs used in this study have not
perturbed any natural dimerization of the domain in solution). Molecular weights were
calculated based on elution volume and comparison with Gel Filtration Standard (BioRad).
4-2. Probing the binding properties of the obligate Shank3 PDZ domain
monomer and dimer'
In the first dimerization approach, the ligand affinities of two fusion constructs of the
Shank3 PDZ domain, GST-Shank3PDZ-FLAG and GB1-Shank3PDZ-His6 , were compared.
The GB1 domain is a small fusion partner that is known to enhance the expression and
solubility of the corresponding protein constructs.15 While the favorable properties of the
GB1 fusion tag indicate monodispersity of GB1 fusion proteins, the GST fusion tag itself has
been shown to homodimerize with a crystallographic 2-fold symmetry. 6 Interestingly, these
two constructs showed very different ligand-binding affinities. Titrations with the fluorescent
probe demonstrated a 30-fold difference in affinity between the two constructs, a significant
difference in ligand-binding behavior. Size exclusion chromatography (SEC) confirmed that
GB1-Shank3PDZ behaves exclusively as a monomer, while GST-Shank3PDZ is exclusively a
.............  
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dimer (Figure 4.3). The probe bound to (monomeric) GB 1 -Shank3PDZ with a dissociation
constant (KD) of 4.7 M ± 1.1 [M and to (dimeric) GST-Shank3PDZ with a KD of 0.15 [M ±
0.06 [M (Figure 4.5). This 30-fold difference in KD would be significant in the context of
protein / ligand-binding in vivo.
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Figure 4.5. Ligand binding to obligate monomer and dimer of Shank3 PDZ domain. A)
Titration of fluorescence-based probe with GB1-Shank3PDZ (monomer) and corresponding
data fit. B) Titration of fluorescence-based probe with GST-Shank3PDZ (dimer) and
corresponding data fit. Representative titrations, KD and standard deviation from at least three
trials. Peptide concentration 3 tM, protein concentrations from 0 to > 25 [M.
Several control experiments confirm that the higher affinity for the GST construct
does not result from nonspecific interactions of the fluorophore. The fluorescent probe
displays no appreciable fluorescence increase (less than 1.5-fold) or binding affinity when
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titrated with GST domain alone. Non-optimal fluorescent probes, with the fluorophore at the
(-)6 and (-)4 positions in the peptide, as opposed to the optimal (-)5 position, yield less than
4-fold increase in fluorescence with saturating GST-Shank3PDZ protein construct (see Figure
4.1 caption for numbering convention). This is less than 1.5% of the fluorescence increase
observed with the optimized probe. These results establish that the greater fluorescence
signal of the probe with the GST protein construct does not result from nonspecific
interactions of the 4-DMAP fluorophore with the protein construct.
Additionally, ITC studies of the probe with GB1-Shank3PDZ and GST-Shank3PDZ
constructs yield dissociation constants of 2.9 tM ± 1.3 [tM and 0.2 [tM ± 0.1 [tM,
respectively. These values agree well with those obtained by fluorescence titration, and
demonstrate that the fluorescence titration method is still robust in this application. Overall,
the probe does in fact bind with a significantly tighter affinity to dimeric GST-Shank3PDZ
than to monomeric GB1-Shank3PDZ.
4-3. Probing Shank3 PDZ domain monomer and dimer via external
regulator!
A complementary chemical inducer of dimerization approach was taken, in order to
isolate and study the effects of domain dimerization via an external small molecule regulator.
The Fv (FKBP Phe36Val) domain affords this level of control over protein dimerization,
through the chemical inducer of dimerization (CID) AP20187. 4 A Shank3 PDZ domain
construct incorporating the Fv domain was engineered for this study and is shown in Figure
4.6. It should be noted that the design of this construct required semi-empirical optimization.
Specifically, the Fv construct was augmented with a linker region, after preliminary titrations
and a comparative analysis of the Fv dimer and GST dimer crystal structures indicated that
additional flexibility might be necessary to fully allow for PDZ domain dimerization. This
construct was expressed, purified, and tested in both the monomeric and dimeric forms.
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Figure 4.6. Effects of Shank3 PDZ domain dimerization on ligand binding. A) Titration of
fluorescence-based probe with Fv-Shank3PDZ (monomer) and corresponding data fit. B)
Titration of probe with Fv-Shank3PDZ/AP20187 (dimer) and corresponding data fit.
Representative titrations, KD and standard deviation from at least three trials. Peptide
concentration 2 M, protein concentrations from 0 to > 25 [M.
A comparison of the resulting binding titrations highlights the fact that the maximum
fluorescence increase of the fluorogenic probe is much larger for the dimeric Fv-Shank3PDZ
than for the corresponding monomer (see Figure 4.6), a trend that was evident with the
monomeric GB 1 and dimeric GST fusion constructs. Since the fluorescence increase of the
probe is correlated with the polarity of the surrounding environment, these results suggest that
the Shank3 PDZ domain undergoes a structural reorganization upon dimerization, creating a
more hydrophobic, higher-affinity binding pocket for the ligand. The fluorescent probe
bound with an order-of-magnitude tighter affinity to the Fv-Shank3PDZ dimer (KD of 0.41
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M 0.12 rM) than to the corresponding monomer (KD of 4.8 FM t 1.1 pM), mirroring the
results from the GST-Shank3PDZ dimer and GB1-Shank3PDZ monomer, respectively (see
entries 1 and 2 in Table 4.1).
Entry Statea Protein Construct Ligandb KV
1 M GB1-Shank3PDZ Fl 4.7 ± 1.1
D GST-Shank3PDZ F1 0.15 ± 0.06
2 M Fv-Shank3PDZ Fl 4.8 ± 1.1
D Fv-Shank3PDZ+AP Fl 0.41 ± 0.12
3 M Fv-Shank3PDZ GKAP 1.0 ± 0.1
D Fv-Shank3PDZ+AP GKAP 0.12 ± 0.01
Table 4.1. Dissociation constants from fluorescence titrations and competition experiments.
'M = monomer, D = dimer. bFl = fluorescent probe; GKAP = non-fluorescent GKAP ligand.
cKD represented as mean t standard deviation, from at least three trials. Note that the numbers
given in entry 3 are Ki values.
Control titrations of Fv domain alone and AP20187 alone with fluorescent probe show
negligible fluorescence increase (less than 2-fold in each case). These results again confirm
that the fluorescence increases observed in the Fv-Shank3PDZ monomer and dimer titrations
arise from specific interactions between probe and the cognate PDZ domain. Size exclusion
chromatography studies reveal that the Shank3 PDZ domain alone (with and without His6 tag)
is a monomer in solution, demonstrating that the N- and C-terminal tags do not interfere with
any natural ability of the Shank3 PDZ domain to dimerize individually. Overall, these studies
establish that in vitro, the designed fluorescent probe binds with an order of magnitude higher
affinity to the dimerized Shank3 PDZ domain than to the monomeric form.
4-4. Effects of dimerization on a biologically-relevant ligand'
The observed difference in affinity could be of potential significance in the PSD, if the
magnitude of this effect also translates to natural (non-fluorescent) ligands. In this context,
experiments were performed to investigate the effect of Shank3 PDZ domain dimerization on
binding affinity of the GKAP ligand (C-terminal peptide of the GKAP protein). In order to
determine these affinities via titration, competition experiments were performed in which
non-fluorescent GKAP gradually displaced fluorescent probe bound to protein. As shown in
Figure 4.7, these data were fit to yield dissociation constants for the unlabeled GKAP peptide
with both the monomeric and dimeric forms of Fv-Shank3PDZ.
The binding affinity of the unlabeled GKAP peptide is significantly affected by the
oligomerization state of Shank3. GKAP binds with an 8-fold higher affinity to dimeric
Shank3 PDZ domain (Ki = 0.12 [M t 0.01 [tM) than to the monomeric domain (Ki = 1.0 JAM
- 0.1 [tM). This difference in affinity follows the trend found in the previous studies utilizing
the fluorescent probe (see Table 4.1), and demonstrates that the natural interaction between
GKAP and the Shank3 PDZ domain can also be tuned by PDZ domain dimerization. In
effect, dimerization of the Shank3PDZ domain pushes the equilibrium of its ligand-binding
process significantly toward ligand-bound protein, a change that would have a large effect in
the pool of PDZ domain-mediated interactions at the synapse. Taken together, the results
presented here implicate PDZ domain dimerization as a potential modular control mechanism
for ligand binding in the biological context.
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Figue 47. atafit ofcompetitive titrations of unlabeled GKAP versus fluorescent probeI
Shank3PDZ complexes. A) Fit of competition experiment in which 0 to 10 equivalents of the
non-fluorescent GKAP was sequentially added to a 10 tM solution of fluorescent probe and
Fv-Shank3PDZ. B) Fit of competition experiment in which 0 to 25 equivalents of the non-
fluorescent GKAP was sequentially added to a 2.5 [tM solution of fluorescent probe and Fv-
Shank3PDZ/AP20187. Representative titrations, KD and standard deviation from at least three
trials. The imperfect fit is most likely caused by slightly different binding modes of the two
different peptide ligands used in the competition experiments.
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Conclusions
Investigations into the macromolecular complexes that govern the structure and
function of the neuronal PSD continue to point to the significance of multimeric interaction
motifs, especially with respect to PDZ domains. The tandem PDZ domains of proteins such
as PSD-95 have been shown to work together, relying upon this synergy to function properly
in their interactions with protein ligands.17' ' Homodimers of glutamate receptor-interacting
protein (GRIPI) PDZ6, zonula occludens (ZO) PDZ2, and Shank1 PDZ have been reported,
all with different relative orientations of the monomer components.19, 20 The dimerization of
GRIP1-PDZ6 is proposed to enable the efficient clustering of synaptic GRIP-binding
proteins,2 1 and PDZ domain dimers of ZO proteins may provide a structural basis for the
polymerization of claudin protein targets.20
In this study, the optimized fluorescent probe technology discussed in chapter 2 of this
thesis has been used in conjunction with controlled protein dimerization to probe the effects
of Shank3 PDZ domain dimerization on ligand binding, a relevant investigation in light of the
functional effects of other PDZ domain homodimers that have been reported. Specifically,
fluorescence titrations, isothermal titration calorimetry, and competition experiments all
demonstrate that the Shank3 PDZ domain may function as a homodimer to achieve significant
(8- to 30-fold) enhancement of ligand-binding affinities. Shank3 PDZ domain
oligomerization state regulates the binding affinity of partner ligands in vitro, and the
magnitude of the effect of dimerization suggests its potential as a regulatory mechanism for
the formation of large synaptic multiprotein complexes in neurons. Since PDZ domains
regulate signaling cascades that often rely upon the clustering of target proteins, it is perhaps
not surprising that the dimerization of the Shank3 PDZ domain would exert significant control
over the PDZ/ligand binding interaction. Overall, these in vitro studies have led to a more
comprehensive insight into the regulation of the Shank3 PDZ domain and have provided a
foundation from which to begin designing experiments in cells. Future studies to probe the
functional effects of Shank3 PDZ domain dimerization in neurons will clarify the degree to
which this mechanism controls Shank3 PDZ domain ligand binding in the biological context.
Experimental Methods
Solid phase peptide synthesis (SPPS) and fluorophore insertion. Peptides were obtained
either by manual synthesis or with an automated synthesizer (Advanced ChemTech automated
synthesizer model 396 Q) using standard Fmoc SPPS procedures. Manual syntheses were
performed on a 0.02 mmol scale with TGT resin (~0.2 mmol/g), using Fmoc-protected amino
acid (6 equivalents), HBTU / HOBt coupling reagents (6 equivalents), and DIPEA (12
equivalents) in NMP. Couplings were done with a 50 mM amino acid solution for
approximately 1 hour. Fmoc deprotection was achieved after each coupling step by treatment
of the resin with a solution of 4-methyl-piperidine in DMF (20% vol/vol) for 3 x 5 minutes.
The free amine of the N-terminal residue of the peptide was acetyl capped by treatment with a
solution of acetic anhydride and pyridine (0.15 M each in DMF).
Peptides incorporating the 4-DMAP environment-sensitive fluorophore were synthesized
using the on-resin derivatization approach previously reported.23 An Alloc-protected
diaminoacid (Fmoc-L-Dab(Alloc)-OH from AnaSpec) was incorporated into the peptide
sequence during the initial coupling SPPS procedure described above. After N-terminal
acetyl capping, the resin was resuspended in dry dichloromethane (20 mM in peptide) with a
stream of N2 bubbling through the solution for 5 minutes. Pd(PPh3)4 (0.8 equivalents) and
phenylsilane (25 equivalents) were then added to remove the Alloc group, and the bubbling of
the solution was maintained for another 15 minutes. The resin was washed with
dichloromethane, and the degassing/deprotection cycle was repeated two additional times.
The free amine of the resulting peptide on resin was then reacted with a solution of the 4-
DMAP anhydride (4-N, N-dimethylaminophthalic anhydride, 2 equivalents, 50 mM) and
DIPEA (4 equivalents) in NMP overnight. The resin was washed with DMF and
dichloromethane, and ring closure was performed by treatment with a solution of
HBTU/HOBt (6 equivalents, 50 mM) in NMP with DIPEA (12 equivalents) for
approximately 1 hour. The resin was then washed with DMF and dichloromethane, and the
washing/coupling cycle was repeated two additional times in order to achieve complete ring
closure.
Peptides were deprotected and cleaved from the resin with a TFA / H20 / TIPS (95:2.5:2.5)
cleavage cocktail for 2.5 to 3 hours. TFA was evaporated until the peptides precipitated, and
the residue was then triturated and precipitated in cold ether before purification by reverse
phase HPLC on a semi-preparative column (YMC-Pack Pro Cis, ODS-A 5/120, 250X20 mm)
in water (0.1% TFA) using an acetonitrile (0.1% TFA) gradient and monitoring at 228 nm and
350 nm. Peptides were characterized by analytical HPLC and MALDI-TOF mass
spectroscopy. Peptides were lyophilized and stored at - 80 'C.
Fluorescent GluR1 peptide sequence: Ac-NRRSGkPPGATGL-COOH where k =
norleucine (replaced native methionine) and P = Dab(4-DMAP); expected mass = 1512.8,
mass obtained = 1513.7.
Control Fluorescent GluRi peptide sequence GluR1-4b: Ac-NRRSGkPLATGL-
COOH; expected mass = 1568.9, mass obtained = 1571.0.
Control Fluorescent GluR1 peptide sequence GluR1-6b: Ac-NRRSGkpLGATGL-
COOH; expected mass = 1528.9, mass obtained = 1530.0.
GKAP peptide Ac-<pNRRIYIPEAQTRL-COOH where cp = p-nitrophenylalanine
(which has been included to provide a handle for quantification purposes); expected mass =
1862.9, mass obtained = 1862.5.
Cloning of Shank3 PDZ domain constructs. The PDZ domain of Shank3 (residues 635 to
749, from UniProtKB/Swiss-Prot entry Q9JLU4), was PCR-amplified using the primers 5'
-CGG GAT CCG AGA ACC TGT ACT TCC AGG GCT CAC ACA GTG ATT ATG TCA
TTG ATG and 5' -CCG GAA TTC TTA CTT ATC GTC ATC GTC CTT GTA GTC TGC
GCC GAG CAC TAT CCT CCT CTG G, as described in Chapter 2 of this document. The
PCR-amplified inserts were digested with BamHI/EcoRI and ligated into a BamHI/EcoRI-
digested pGEX-4T-2 vector (GE Healthcare) for GST-TEV-Shank3PDZ-FLAG.
In order to replace the C-terminal FLAG tag with a His6 tag, the following primers and
their reverse complements were ordered and used in two 2-stage PCR protocol" for
QuikChange@ Site-directed Mutagenesis (the first to remove the FLAG tag, the second to
insert the His6 tag): 5' -GC CAG AGG AGG ATA GTG CTC GGC GCA TAA GAA TTC
CCG GGT CGA CTC GAG CG- and 5' -GC CAG AGG AGG ATA GTG CTC GGC GCA
CAC CAC CAC CAC CAC CAC TAA GAA TTC CCG GGT CGA CTC GAG CG-.
The PDZ domain of Shank3 (residues 635 to 749) was PCR-amplified using the
primers 5' -CGG GAT CCG AGA ACC TGT ACT TCC AGG GCT CAC ACA GTG ATT
ATG TCA TTG ATG- (same as above) and 5' -CCG CTC GAG GCG CCG AGC ACT ATC
CTC CTC TGG-. The PCR-amplified inserts were digested with BamHI/XhoI and ligated
into a BamHI/XhoI-digested pGBH vector (proided by Dr. H.-Y. Hu) for GB1-TEV-
Shank3PDZ-His6.
The codon-optimized Fv-Shank3PDZ construct (residues 635 to 749 of Shank3) was
ordered from Bio Basic Inc. A maxiprep of the DNA was digested with NdeI/XhoI, and the
desired gene was ligated into a NdeI/XhoI-digested pET-24a(+) vector.
In order to insert a linker (10 amino acids, GGGENLYFQG) between the Fv and
Shank3PDZ domains, the following primer and its reverse complement were ordered and used
in a 2-stage PCR protocol24 for QuikChange@ Site-directed Mutagenesis: 5' -CTG GAG
GGA TCC GAA TTC GGC GGT GGC GAG AAC CTG TAC TTC CAG GGC TCT CAT
TCT GAT TAC GTT ATC-.
The full nucleotide sequence for the final Fv-Shank3PDZ construct used in these
experiments is as follows: 5' -GAT ATA CAT ATG GGC GTT CAG
CCG GGT GAT GGC CGT ACC TTC CCG AAA
CAT TAT ACC GGT ATG CTG GAA GAT GGC
GAC CGC AAC AAA CCA TTC AAA TTT ATG
GGT
CTG
ATC
CTG
TCT
CGT
ACT
TAT
CGT
GTT
CTG
GCA
TGG GAA GAA GGT
ACC ATT TCC CCG
ATT CCG CCG CAC
GAG GGA TCC GAA
CAT TCT GAT TAC
GAT CAC
CCG ATT
CTG GAA
ACC GGT
GGT CAC
GTG
CGT
GTG
GAC
GCC
TTC
GTT
ATC CGC
GCA AAG
CCG GGT
CTG AAA
CAG GGC
CAG AAG
GCG GAA
CTG CAG
GGT CTG
GTT AAA
AAC CGC
GAC AGC
CGC GGC
AAA AAG
CTG GGT
GCG CAG ATG TCC
TAC GCC TAC
ACC CTG
GGC GGT
ATC GAC
GAG GGT TTC GGT TTC
GAG GAA TTT ACC CCG
AGC GTG GAC GTA GAG
GAC TTC CTG ATC GAA
AAA CAG GTG GTA GGC
GTT
GGC
GAT
GTG
ACT
GGT
GTT
CTG
GGC
TTT
GAG
AAA
CTG
CCG
GTA
AAT
ATC
GTT GAA
CAG ACC
GTG GAT
AAA CAA
GTT GGC
GCG ACT
GAC GTA
AAC CTG
GTT GCT
CGT GGC
GCT TTC
GCT TGG.
GGC GTG
CGC CAA
ACT
TGC
TCT
GAA
CAG
GGT
GAA
TAC
ATC
GCT
CCA
AAA
AAC
GGT
ATG AAA GTT GTT TCC GTA ACT CGT AAA CCG GAA GAA
CGT CTC GAG CAC CAC CAC CAC CAC CAC TGA- 3'.
TCT
GTT
CGT
ATC
GTT
AGC
GTG
CGT
CAC
CTG
TTC
CTG
AAA
GCA
GCG
GTT
GGC
The PDZ domain of Shank3 (residues 635 to 749) was PCR-amplified using primers
to introduce a 5' NdeI restriction site and a 3' XhoL restriction site. The PCR-amplified
inserts were digested with NdeI/XhoI and inserted into a modified pET32a vector (Novagen),
yielding the His 6-TEV-Shank3PDZ construct.
Expression and purification of Shank3 PDZ domain constructs. E. coli BL21 codon plus"
(DE3)-RIL or RP cells were transformed with each of the expression plasmids. Cells were
amplified in 0.5 L of an auto-inducing medium (ZYM-5052, see reference for composition
details) at 25 *C for 24 hours,2 5 or in 1 L of Luria-Bertani media (at 37 'C until an optical
density of 0.6-0.8 was achieved, then at 16 'C for 16 hours after induction with IPTG).
For GST-Shank3PDZ, cells were harvested by centrifugation and the pellet was
resuspended in lysis buffer (100 mM EDTA, 10% glycerol, 1% TritonX-100, 1 mg/mL
Lysozyme in PBS, pH 7.4) containing protease inhibitor cocktail III (Calbiochem). Cells
were lysed by ultrasonication (Branson Sonifier 450 at 40% power with a 40% duty cycle for
4 min at 4 C). After addition of 1 mL of a 1 mM solution of DTT in water, the lysate was
cleared by centrifugation (15,334 g, 40 minutes, 4 C). The GST-Shank3 was purified with 5
mL of Glutathione SepharoseT M 4 Fast Flow (GE Healthcare) by batch binding. The bound
proteins were washed with 20 volumes of PBS (pH 7.4) and eluted with 2 volumes of a 10
mM glutathione in 50 mM Tris (pH 8) solution.
For GB1-Shank3PDZ, Fv-Shank3PDZ, and His6_TEV-Shank3PDZ, cells were
harvested by centrifugation and the pellet was resuspended in lysis buffer (300 mM NaCl, 50
mM PO43 , 10 mM imidazole, 2 mM p-mercaptoethanol, 1% NP-40, 1 mg/mL Lysozyme, pH
8.0) containing protease inhibitor cocktail III (Calbiochem). Cells were lysed by
ultrasonication (Branson Sonifier 450 at 40% power with a 40% duty cycle for 4 min at 4 C).
The lysate was cleared by centrifugation (15,334 g, 40 minutes, 4 C). The proteins were
purified with 5 mL of Ni-NTA Agarose (Qiagen) by batch-binding. The bound proteins were
washed with 7 volumes of wash buffer (300 mM NaCl, 50 mM P0 43 , 20 mM imidazole, 2
mM P-mercaptoethanol, pH 8.0) and eluted with 2 volumes of elution buffer (300 mM NaCl,
50 mM PO4 3 , 250 mM imidazole, 2 mM p-mercaptoethanol, pH = 8.0).
For all constructs, fractions were analyzed by 12% SDS-PAGE followed by
Coomassie staining and Western blotting (anti-FLAG or anti-His6). Fractions containing the
protein were pooled, diluted and dialyzed against PBS (pH 7.4). Protein concentrations were
measured by determining the absorption at 280 nm in 6 M guanidinium chloride. Purified
protein solutions were aliquoted, flash-frozen and stored at -80 'C in PBS (pH 7.4) until use.
For TEV cleavage of the His6-TEV-Shank3 construct, the protein (in 10 mL volume)
was dialyzed into 1x TEV buffer (50 mM Tris HCl pH 8, 100 mM NaCl, 0.5 mM EDTA, 1
mM DTT, 2.5% glycerol), 1.5 mg of TEV protease was added to the dialysis cartridge, and
the cleavage was allowed to proceed under dialysis conditions for 3 days at 4 degrees Celsius.
Completion of the TEV cleavage reaction was monitored by Coomassie and Western blot
analysis.
Controlled dimerization of Fv-Shank3-His 6 . Fv-Shank3PDZ was dimerized with the
AP20187 small molecule dimerizer supplied by Ariad. The material was reconstituted in
ethanol and stored as specified in the Argent TM Regulated Homodimerization Kit v. 2.0. Prior
to titrations, Fv-Shank3PDZ was incubated with AP20187 (exactly half the concentration of
the Fv-Shank3 concentration, no greater than 60 [M protein and 30 iM AP20187) on ice for
5 minutes. This stock solution of dimerized Fv-Shank3PDZ was then used in titrations.
Figure S2 shows that Fv-Shank3PDZ + AP20187 runs as a homogeneous dimer on an
analytical SEC column, confirming that a homogeneous solution of dimerized protein is
obtained by this method.
Size exclusion chromatography (SEC). Each protein sample (100 [L, 10-50 tM) was
injected onto a 200 [tL injection loop of the FPLC. These samples were run with a solution of
PBS buffer (pH 7.4) through a Superdex@ 75 analytical SEC column. Blue Dextran was run
on the column to determine the void volume. Either BioRad Gel Filtration Standard or
Ribonuclease A, Ovalbumin, and Albumin standards were run, and a calibration curve of Kay
vs. log(MW) allowed for subsequent determination of the molecular weight of the Shank
construct protein samples through equation (1) below (where V, = elution volume; V0 = void
volume; Vc = column volume = 24 mL).
V -V
K = "(1)
100
Fluorescence titrations. Fluorescence titrations were performed to determine the KD Of
fluorescent peptide / protein pairs. For each titration, the peptide concentration was kept
constant (between 1 and 20 [tM) and the protein concentration was varied from values close
to the expected KD to saturation of fluorescence signal. A separate solution (150 tL) in PBS
buffer (pH 7.4) was prepared for each protein concentration. Dissociation constants were
evaluated using SPECFIT/32 TM Global Analysis System for Windows (version 3.0.39), taking
into account wavelengths from 432 nm to 730 nm. The results from at least three independent
titrations were averaged together, and the average with the standard deviation is reported here.
Competitive titrations. Competition experiments were performed on a PBS (pH 7.4) solution
(450 [tL, containing either 10 tM fluorescent peptide and 10 tM Fv-Shank3 PDZ domain or
2.5 tM fluorescent peptide and 2.5 tM Fv-Shank3 PDZ domain in the presence of 1.25 1iM
AP20187). The concentrated (> 5 mM) non-fluorescent peptide solution was added
sequentially in small volumes to achieve a range of concentrations (from 1 nM to 30 tM).
The KD of the non-fluorescent peptide was obtained by fitting the relative fluorescence
increase (RFI, the quotient of the fluorescence intensity at the wavelength of maximum
emission divided by the fluorescence intensity of peptide without the presence of protein at
that wavelength) to the logarithm of the non-fluorescent peptide concentration (Log[nFP],
Molar). This was performed using the Competitive Binding: One Site model from GraphPad
Prism 5 software, which uses the following equations:
log(EC50) = log 101og(K)(1 + (2)
maxmI - minRFIRFI = minRFI 1 + o(log[nFP]-log(EC50))
where [FP] is the concentration of the fluorescent peptide, KDHuo is the dissociation constant of
the fluorescent peptide with the corresponding Fv-Shank3PDZ form (constant, same units as
[FP]), minp is 1 and max, is the RFI in the absence of competitive ligand. The results of at
least three independent competition titrations were averaged together (and the standard
deviation of these values was calculated) to yield the values reported.
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Chapter 5
Development of Chemical Probes for Investigation of the C.
elegans Lin-10 PDZ Domains
Introduction
The study of neuronal receptors and proteins is aided immensely by C. elegans
investigations involving genetic manipulation, electrophysiology, behavioral models, and
fluorescence studies. C. elegans is a multicellular eukaryote, and is a well-defined model
organism. Each worm contains exactly 302 neurons, and their connectivity pattern has been
completely mapped. Novel proteins for neuronal receptor function have been discovered in
the worm, and have led to a better understanding of neuronal signaling in vertebrates.
There are at least ten glutamate receptor subunits that have been found in C. elegans,
two of which (GLR- 1 and GLR-2) are clear homologues of AMPA-type mammalian receptor
subunits based on sequence identity.' Studies toward understanding the localization of these
receptors in C. elegans provide direct evidence that PDZ proteins are required for localization
of the GLR- 1 neurotransmitter receptor to central synapses in vivo. Specifically, these studies
point to the PDZ-domain containing protein Lin-10, which is expressed in C. elegans vulval
epithelial cells and in neurons.2
Utilizing GFP fusion constructs of GLR-1, researchers have shown that proper
localization and function of GLR-1 in both neurons and epithelia requires Lin-10. However,
the mechanism by which Lin-10 assists GLR-1 is not understood. The simplest model for the
role of Lin-10 in the proper assembly of glutamatergic synapses invokes the direct binding of
the Lin-10 PDZ domain(s) to the C-terminus of GLR-1. However, researchers have been
unable to detect binding of Lin-10 to GLR-1 in a variety of in vitro assays, suggesting that
Lin-10 plays a more indirect role in GLR-1 receptor targeting.3
GLR-1 is a class I PDZ domain ligand, which has the C-terminal consensus sequence
[T/S]-X-$ (where $ is a hydrophobic amino acid). This is in contrast to class 1I PDZ domain
ligands, which display a $-Xaa-$ C-terminal consensus sequence. Interestingly, while GLR-1
synaptic localization is disrupted in Lin-10 null mutants, it can be restored via changes to the
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C-terminus of GLR-1. Specifically, replacement of the GLR-1 C-terminal class I consensus
sequence (-TAV) with a class II sequence (-FYV) restores GLR-1 synaptic localization in
these mutants. This demonstrates that these C. elegans neurons utilize at least two separate
post-synaptic localization pathways, one of which involves the Lin-10 protein and both of
which have yet to be completely defined.3
Due to the observed role of Lin-10 in receptor stabilization and function, and the
likelihood of PDZ domain involvement in these interactions, probes for the PDZ domains of
Lin-10 were targeted in this study. Specifically, the goal was to screen for optimal fluorescent
probes, to adapt the probe design for in vivo studies, and to use them to both visualize Lin-10
localization in C. elegans and to study the effects of competing out natural Lin-10 PDZ-ligand
interactions.
Results and Discussion
5-1. Initial ligand screening for Lin-10 probes
In order to learn more about the function of the Lin-10 protein in C. elegans, probes
were designed for its PDZ domains, Lin-10 PDZ-12. These PDZ domains are organized in
tandem, similar to the first two PDZ domains of PSD-95. However, unlike the class I PSD-95
PDZ-12, this Lin-10 tandem appears to contain one class I domain and one class II domain
(see sequence alignment, Figure 5.1).
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Figure 5.1. Sequence alignment of PDZ domains from C. elegans Lin-10 and R. norvegicus
PSD-95. The PDZ GLGF loop is present in Lin-10, albeit with modifications to the first and
last residue of the consensus sequence. The class I conserved His residue is present in Lin-10
PDZ-2, but not PDZ-1, indicating that PDZ-1 is a class I-like PDZ domain. Lin-10 PDZ-2
displays 89% sequence homology with the class I PDZ-2 of PSD-95.
The Lin-10 PDZ domains were cloned as GB1 fusion proteins, since the GB1 domain
has shown favorable properties as a fusion tag for the PDZ domain constructs. Due to the
proximity of the two domains in Lin-10, they could function as a cooperative tandem; thus,
the domains were tested both as a tandem and in isolation. The following constructs were
cloned, expressed, and purified: GB 1 -Lin- 1OPDZ-12-His6 , GB1-Lin-1OPDZ-1-His 6 , and GB1-
Lin-1OPDZ-2-His6.
Due to the lack of knowledge regarding Lin-10 PDZ domain binding partners, a
variety of class I and II probes were tested. The probes listed in Table 2.1 of chapter 2
showed negligible fluorescence increase with the Lin-10 PDZ domains. The remaining
probes tested are listed in Table 5.1, along with their characterization. Interestingly, most
ligands showed negligible fluorescence increase in the presence of the Lin-10 PDZ constructs,
except for those based on the class I C-terminal peptide of the AN2 protein, a transmembrane
protein implicated in the control of cell migration.' Even the GKAP probes, which like AN2
probes bind to the Shank3 PDZ domain, showed less than 2-fold increase in the presence of
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Lin-10 protein. The class I Kvl.4,4 CRIPT, and Stargazin probes also exhibited negligible
fluorescence increase, as did the class II GluR24 probe.
# Origin Peptide Sequencea Formula Mass Masab
expected obtained [MB]+
1 Kv1.4 A.SMKAYETDV-c-(= C5 4BUN 14021  1262.6 1262.9
2 Kv1.4 e-SNKVETDV..C0C C,5., 4N14021  1276.7 1278.7
3 Xv1.4 A.SNRKYVETDV-coon C5 6 OGN14021  1290.7 1292.7
4 GKUP ARIYIPAQTRL-coo CUR23 N2 6021  1915.4 1917.1
5 AN2 gNRPARLN1QY1aV-coon C76H11 N270 21  1744-3 1741.0
6 AN2 AfNRRARLQQYWV.-,Q0 C83R2 1 N27 020  1816-4 1914.4
7 AN2 J3RPARL0GQXWV-coo C* 4 IuN 27 02 1830.4 1928.4
8 AN2 .NRRPARLGQYWL-coo C 5NssN27020  1844.4 1842.7
9 AN2 ANRRPARLGQYW-con C 5Eu 5N27020  1944.4 1842.6
10 AN2 A.NRRPARLGQYWV.-coo C96UN 2702O 1858.4 1856.6
11 GluR2 IjRVYG@ESVKI-COOK C77BUON 2402 3  1749.2 1754.4
Table 5.1. Probes used in the initial screening of Lin-10 PDZ domain constructs. aa = Dap(4-
DMAP), P = Dab(4-DMAP), y = Orn(4-DMAP), 6 = Lys(4-DMAP), the NRR sequence was
added on the N-terminus of peptides to improve solubility at high concentrations, as low
solubility of the probe leads to high background fluorescence signal due to aggregation.
b Masses were determinated by MALDI-TOF spectroscopy.
AN2 probes 6-9 from Table 5.1 yielded reasonable fluorescence increases with the
Lin-10 PDZ domain constructs, and these results are displayed in the first four entries of the
Figure 5.2 bar graph. It is evident from these results that the fluorescence increases for Lin-
10 PDZ-1 and Lin-10 PDZ-2 were not additive, since the fluorescence increase of the Lin-10
PDZ-12 tandem was consistently greater than the sum of its single domain counterparts. This
points to the fact that the domains may act in tandem, either (1) by structurally stabilizing one
another and allowing for proper domain folding, or (2) by enhancing one another's ligand
binding ability.
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Figure 5.2. Fluorescence increase results for first generation probes 6-9 (Table 5.1) and
second generation probes 12-15 (Table 5.3) with Lin-10 constructs.
Fluorescence titrations of these four first generation probes yielded dissociation
constants and overall fluorescence increases reported in Table 5.2. Based upon both
dissociation constant and relative fluorescence intensity increases, probes 6 and 9 were carried
further.
# Origin Peptide Sequnno*m 4 (pa)
6 AN2 kiMPARLaGQYWV--co 17. 3 * 1. 6 19
7 AN2 kPhBARLOGYNITWc.. 36.2 * 3.0 15
8 AN2 At..RRPARLPGQYWL-c= 31.4 * 2.3 18
9 AN2 RPARLyGQYWC00 34.2 * 3.1 40
Table 5.2. Dissociation constants and overall fluorescence increases from fluorescence
titrations of probes 6-9 with Lin-10 PDZ-12. aa = Dap(4-DMAP), P = Dap(4-DMAP), y =
Orn(4-DMAP), the NRR sequence was added on the N-terminus of peptides to improve
solubility. bRFI = relative fluorescence increase.
Interestingly, the AN2 peptide sequence could be classified as both a class I and class
II ligand, since the Tyr residue at the -2 position of the peptide contains a hydrophobic
aromatic ring and a hydroxyl group. Therefore, a second generation of probes was pursued,
in which the -2 residue of probes 6 and 9 was replaced with both Ser and Phe to mimic class I
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and class II ligands, respectively. Characterization of these second generation probes 12-15 is
provided in Table 5.3, and initial fluorescence results with the Lin-10 protein constructs are
shown in the last four entries of Figure 5.2.
# Origin P.ptide Sequencea Formla Mass a
expected obtained [NM]+
12 AN2 JRUEPARLaCQYFV-cons C91 moN2AO2 o 1777.4 1779.7
13 AN2 ,.NRRARLaGQYSV-_ -5H 1ANA 1  1717.3 1719.5
14 AN2 .NRRPARLyGQYFV-coN Cse-UA 2AO2 o 1805.4 1909.9
15 AN2 -MRPARLY6QYSV-coou C.,uNAA2  1745.3 1744.4
Table 5.3. Second generation probes 12-15 and their characterization. aa = Dap(4-DMAP), y
= Orn(4-DMAP), the NRR sequence was added on the N-terminus of peptides to improve
solubility. bMasses were determinated by MALDI-TOF spectroscopy.
The results from the second generation probes suggested that the Lin-10 tandem binds
class I ligands, as probes 13 and 15 exhibit greater fluorescence increases than probes 12 and
14. This was further corroborated by the dissociation constants of probes 13 and 14 for the
Lin-10 PDZ-12 tandem, shown in Table 5.4. Overall, first generation probe 6 and the
corresponding class I derivative 13 yielded the lowest dissociation constants for the Lin-10
tandem, and probe 13 yielded the highest fluorescence increase. Hence, these two probes
were taken forward for further derivatization and application in vivo.
# Origin Peptide Sequencea No (pN) RIa
13 AN2 A. RPARLaGQSV-coon 18.7 * 2.3 41
14 AN2 I A.RRPARLyGQYFV-cooN 29.7 * 4.5 26
Table 5.4. Dissociation constants and overall fluorescence increases from fluorescence
titrations of probes 13 and 14 with Lin-10 PDZ-12. aa = Dap(4-DMAP), y = Orn(4-DMAP),
the NRR sequence was added on the N-terminus of peptides to improve solubility. b RFI =
relative fluorescence increase.
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5-2. Cell-permeant second generation probes
In order to apply these Lin-10 probes to in vivo tests in C. elegans, probes 6 and 13
were functionalized with the 11-residue TAT sequence,6 a truncated portion of the HIV-1 Tat
protein basic domain that can confer cell permeability to appended ligands. The TAT
sequence was appended to the N-terminus of probes 6 and 13, and the resulting probes 16 and
17 in Table 5.5 were tested in titrations with the Lin-10 PDZ-12 tandem. In addition to these
two probes, a third TAT-control probe, 18, was synthesized. The C-terminal amide and Arg
residues at positions (-)1 and (-)3 of the control probe prohibit it from binding to PDZ
domains.
# Origin Peptide Sequencea k (IM) Rib
16 AN2 A.YI-RCORRQRRRPARL Q-o 33 * 1.8 23
17 AN2 AYRRnRQRRRPAaGQYSV,-coo 29.0 * 2.2 33
18 control A.RRRR RTRPR -=a 560 300 1.5
Table 5.5. Dissociation constants and overall fluorescence increases from fluorescence
titrations of TAT probes 16 and 17 and control 18 with Lin-10 PDZ-12. aa = Dap(4-DMAP),
NRR residues have been replaced with TAT sequence.b RE = relative fluorescence increase.
The TAT-control peptide did not bind to the Lin-10 PDZ-12 construct or show any
appreciable fluorescence increase in the presence of the protein. Both probes 16 and 17
showed slightly increased dissociation constants in comparison to their parent probes 6 and
13, which was attributed to some small interference of the TAT sequence with binding to the
tandem domains. However, the dissociation constants and relative fluorescence increases for
both probes were still reasonable for initial trials in C. elegans, and therefore these probes
were prepared for testing in vivo while additional avenues were pursued to increase probe
affinity in a third generation of Lin-10 PDZ-12 probes.
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5-3. Initial probe testing in C. elegans
Since Lin-10 has been shown to be involved in the localization of GLR-1 to synapses,3
peptides 16 and 17 were tested for inhibitory activity against GLR-1 synaptic localization in
C. elegans. Researchers in the Maricq laboratory injected these peptides into C. elegans
expressing GLR1-GFP in a single pair of AVA neurons. Wild type expression in these
neurons is shown in Figure 5.3, as is expression in a Lin-10 null mutant (lin-10). Note that in
the AVA neurons, the expression of GLR1-GFP was more diffuse in the Lin-10 null
background than in the wild type C. elegans (arrows point to AVA neurons). Also note that
there was background expression of GLR1-GFP in other neurons of the worms, which
accounts for the fluorescent signal elsewhere'in the images. Based on these results, if the Lin-
10 probes did indeed bind to the Lin-10 PDZ domain(s) and out-compete natural interactions
with the GLR1 receptor, lack of localization of these receptors, i.e. more diffuse signal from
GLR1-GFP, would be expected.
Unfortunately, treatments with the inhibitory peptides 16 and 17 did not have much of
an effect on the localization of GLR1-GFP at the AVA neurons (and neither did treatment
with control peptide 18). TAT control, LinlOa, and LinlOb panels still showed punctae of
GLR1-GFP localized at the AVA neurons, similar to the localization in the wild type worms.
It should be noted that in these imaging experiments, a significantly strong effect was needed
to ensure accurate interpretation and observation. Most likely the peptides used in these
studies did not bind strongly enough to the Lin-10 PDZ domains to elicit an effect on GLR1-
GFP localization. Hence, in order to repeat these types of experiments and obtain
interpretable results, inhibitory peptides with dissociation constants in the low micromolar
range, about an order of magnitude tighter than those of peptides 16 and 17, would be
necessary.
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Figure 5.3. Effect of peptides on inhibition of GLR1-GFP synaptic punctae in a single pair of
AVA neurons. AVA shown in yellow in the worm schematic at the top. Wild type
expression of GLR1-GFP (wt), expression in Lin-10 null background (lin-10), wild type
injected with control peptide 18 (TAT), wild type injected with inhibitory peptide 16
(LinlOa), wild type injected with inhibitory peptide 17 (LinlOb).
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5-4. Efforts toward third generation probes
Further investigations in C. elegans necessitate Lin-10 probes with greater affinity. In
order to identify other potential peptide sequences for probes, ligands for the mammalian Lin-
10 homologues (Mint proteins) were investigated. Two such ligands are presenilin7 of the
gamma-secretase protease complex and the motor protein kinesin Kif 7.8 Additionally, it has
been reported that an autoinhibited conformation of the PDZ domains of Mint1 is mediated by
molecular interaction between the conserved C-terminal tail of the protein and the first
domain of the PDZ tandem.9 Interestingly, the -3 residue of the Mint1 and Lin-10 C-terminal
peptides is a proline. This residue is not commonly found at the -3 position among PDZ
domain ligands. Given the conformational constraint imposed by a Pro residue, it is possible
that the Pro allows for autoinhibition in both MINT 1 and Lin-10 proteins. Hence, Mint 1 and
Lin-10 C-terminal peptides (C-peptides) were also tested as potential ligands. Since the Dap
residue for the 4-DMAP fluorophore stood out in the previous screen of ligands for the Lin-10
domains, that linker length was kept constant in the new screen.
# Origin Pptide Sequenea* Formula Mass Maseb
expected obtained [MR]+
19 Presenilin A.DQLAaBQEI-coon C,R90N1,60 1, 1434.9 1430.7
20 Kinesin ASEK8aG8ePL.. CmERN 14020  1210.6 1220.6
21 Lin-10 A.LTQaQPQI.-coo Ca2 9N,1501, 1337.9 1337.3
22 Mint-1 ALTQaQPYI-Coo C63HEN 14O1 8 1333.8 1338.7
Table 5.6. Probes based on Mint PDZ domain ligands, to screen with Lin-10 PDZ domain
constructs. aa = Dap(4-DMAP). bMasses were determinated by MALDI-TOF spectroscopy.
Probes 19-22 were screened against all three Lin-10 PDZ domain constructs, and the
relative fluorescence intensity results are summarized in Figure 5.4. The presenilin probe 19
was the only one to yield promising results. Although the fluorescence increase for this probe
with the Lin-10 tandem was lower than that of the other probes, titration analysis
demonstrated low micromolar affinity for the Lin-10 PDZ-12 tandem (see Table 5.7), the
lowest affinity of any of the Lin-10 probes yet.
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Figure 5.4. Fluorescence increase results for probes 19-22 with Lin-10 constructs.
These promising results led to the derivatization of probe 19 with the TAT sequence
(see probe 23), to render ligand cell-permeant. Unfortunately, addition of the TAT sequence
reduced the affinity of the probe for the Lin-10 tandem by more than 25-fold. Further efforts
to ameliorate this undesired effect of the TAT sequence by lengthening the probe (to 17
residues of presenilin followed by the TAT sequence) helped somewhat, but the resulting
probe 24 still bound more than 15-fold weaker to the Lin-10 tandem than probe 19, and with a
smaller fluorescence increase as well. Further efforts are required to obtain a probe for which
cell permeability and tight binding (a KD in the low micromolar range or less) are not
exclusive properties. This may necessitate the use of a different method to confer cell
permeability to the probes, perhaps one that does not require covalent attachment of the
carrier to the cargo.
# Origin Peptide Sequence* XD (pg) pgb
19 pro A.NRRDQLcaBQFI.-COO 1.9 0 .6 33
23 Pro RQQ QFYI COOK 53 4 27
24 pro GRERRRRRYLVQPF)ADQLAaRQryI- 31 t 4 10
Table 5.7. Dissociation constants and RFI of probes 19, 23, and 24. aa = Dap(4-DMAP), k =
norleucine (replaces native methionine), probes contain either NRR residues or TAT
sequence. RFI = relative fluorescence increase.
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Conclusions
The reach of the fluorescent probes for PDZ domains has been extended to those of C.
elegans. Studies of these critical elements of the neural network in the worm model can
afford information on learning and memory that is relevant to other organisms. Second
generation probes based on the AN2 ligand sequence were tested in C. elegans, but the results
were inconclusive. Eventually the effects of out-competing the Lin-10 PDZ tandem in vivo,
which necessitates probes with tighter affinity for the Lin-10 tandem, will be studied. Toward
this end, a probe based on the presenilin ligand sequence has been developed. This probe has
the desired low micromolar affinity for Lin-10 PDZ-12, but unfortunately this affinity is
greatly affected by the appendage of the cell-permeabilizing TAT sequence. Future directions
should focus on the development of TAT-free methods of probe delivery, and / or the design
of other TAT derivatives that do not interfere with protein binding. In addition, the
monomeric probe may benefit from extension to a dimeric probe, since it binds to a tandem of
two PDZ domains; this option has been explored for other PDZ domains and will be
discussed in Chapter 6.
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Experimental Methods
Peptide Synthesis (SPPS), Fluorophore Synthesis, and Fluorophore Insertion.
Peptides were obtained either manually or with an automated synthesizer (Advanced
ChemTech automated synthesizer model 396 Q) by using standard Fmoc-based solid phase
peptide synthesis procedures. Typically manual synthesis was performed on a 0.04 to 0.02
mmol scale with Fmoc-Val/Leu/Ile-NovaSyn@ TGT resin (0.2 mmol/g) or Fmoc-PAL-PEG-
PS resin (0.2 mmol/g), using standard Fmoc-protected amino acid (6 equivalents),
HBTU/HOBt as coupling reagents (6 equivalents each) and DIPEA (12 equivalents) in DMF
or NMP. Coupling steps were conducted with a 50 mM solution of amino acid (~1 mL per
100 mg of resin) for 1 hour. Fmoc group removal was performed with a 20% solution of 4-
methyl-piperidine in DMF (vol/vol) for 3 x 5 minutes. After removal of the N-terminal Fmoc
group, the resulting free amine was capped with an acetyl group by using an acetic
anhydride/pyridine solution (0.15 M each in DMF).
Peptides incorporating the 4-DMAP environment-sensitive fluorophore were
synthesized using the on-resin derivatization approach previously reported.10 An Alloc-
protected diaminoacid (either Fmoc-Dap(Alloc)-OH, Fmoc-Dab(Alloc)-OH or Fmoc-
Orn(Alloc)-OH from AnaSpec) was initially inserted during the SPPS steps. After capping of
the N-terminal amino group of the peptide sequence, the Alloc-protecting group was
removed. The resin was resuspended in dry dichloromethane (20 mM in peptide) with a
stream of N2 bubbling through the solution for 5 minutes. Pd(PPh 3)4 (0.8 eq.) and
phenylsilane (25 eq.) were then added to the solution, which was maintained under N2
bubbling for another 15 minutes. The resin was then washed with dichloromethane and DMF,
and the degassing/deprotection cycle was repeated two additional times. The resin containing
the free amine was reacted with a solution of the anhydride form of 4-DMAP (4-
dimethylaminophthalenedicarboxilic anhydride, 2 equiv., 50 mM) and DIPEA (4 equiv.) in
NMP. The mixture was allowed to stir overnight. The resin was then washed with DMF and
dichloromethane and ring closure was performed by using a solution of HBTU/HOBt (6
equiv., 50 mM) in NMP or DMF with DIPEA (12 eq.) for 2 hours. The resin was then washed
with DMF and dichloromethane. The coupling/washing cycle was repeated two additional
times in order to achieve full ring closure.
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Peptides were deprotected and cleaved from the resin with a TFA/H 20/TIPS
(95:2.5:2.5) cleavage cocktail for 2.5 to 3 hours. TFA was evaporated until the peptides
precipitated. The peptides were then triturated and precipitated in cold ether before
purification by reverse phase HPLC on a semi-preparative column (YMC-Pack Pro C18, ODS-
A 5/120, 250x20 mm) in water (0.1% TFA) using an acetonitrile (0.1% TFA) gradient and
monitoring at 228 nm and 350 nm. Peptides were stored lyophilized at -80 0C until use.
Peptide Characterization and Quantification. Peptide identity was confirmed by MALDI-
TOF mass spectroscopy (MALDI-TOF, PerSeptive Biosystems Voyager) using DHB as a
matrix. Purity was assessed by analytical reverse phase HPLC (YMC C18 , ODS-A 5/120,
250x4.6 mm) using a standard gradient (5% acetonitrile containing 0.1% TFA for 5 min
followed by 5-95% acetonitrile containing 0.1% TFA over 35 min in water containing 0.1%
TFA at a flow rate of 1 mL/min). The final peptides were quantified using molar extinction
coefficients of either 4-DMAP (E42nm = 6480 M-Icm-1 in water) or p-nitrophenylalanine
(28onm = 12500 M-1cm1).
PDZ Domain Cloning. The cDNA encoding for the genes used for PDZ domain subcloning
were provided by Villu Maricq (University of Utah; Lin-10). The PDZ domains of interest
were cloned into the pGBH vector, 1 which was provided by Dr. Hong-Yu Hu (Shanghai
Institutes for Biological Sciences), using EcoRI and XhoI restriction sites. A TEV cleaveage
site was incorporated between GB 1 and the domain(s).
The first two PDZ domains of Lin-10, Lin-10 PDZ-12 (residues 797 to 976, from
UniProtKB/Swiss-Prot entry 017583), were PCR-amplified and inserted into the pGBH
vector.
The first PDZ domain of Lin-10, Lin-10 PDZ-1 (residues 797 to 893, from
UniProtKB/Swiss-Prot entry 017583), was PCR-amplified and inserted into the pGBH
vector.
The second PDZ domain of Lin-10, Lin-10 PDZ-2 (residues 887 to 976, from
UniProtKB/Swiss-Prot entry 017583), was PCR-amplified and inserted into the pGBH
vector.
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Expression and Purification of PDZ Domain Constructs. F. Coli BL21 codon plusTM
(DE3)- RP cells were transformed with each of the GB 1 fusion protein expression plasmids.
Cells were amplified in 0.5 L of an auto-inducing medium (ZYM-5052, see reference for
detailed composition) first at 37 'C for 4 hours followed by 12 hours at 16 'C. Cells were
harvested by centrifugation and the pellet was resuspended in lysis buffer (300 mM NaCl, 50
mM P04,3- 10 mM imidazole, 2 mM P-mercaptoethanol, 1% NP-40, 1 mg/mL Lysozyme, pH
8.0) containing protease inhibitor cocktail III (Calbiochem). Cells were lysed by
ultrasonication (Branson Sonifier 450 at 40% power with a 40% duty cycle for 4 min at 4 C).
The lysate was cleared by centrifugation (15,334 g, 40 minutes, 4 C). The proteins were
purified with 5 mL of Ni-NTA Agarose (Qiagen) by batch-binding. The bound proteins were
washed with 7 volumes of wash buffer (300 mM NaCl, 50 mM P0 43-, 20 mM imidazole, 2
mM P-mercaptoethanol, pH 8.0) and eluted with 2 volumes of elution buffer (300 mM NaCl,
50 mM P0 4 3-, 250 mM imidazole, 2 mM @-mercaptoethanol, pH = 8.0). Fractions were
analyzed by 12% SDS-PAGE followed by Coomassie staining and Western blotting (anti-
FLAG). Fractions containing the protein were pooled and dialyzed against PBS (pH 7.4).
Protein concentrations were measured using either the BCA assay (Pierce) with BSA as the
reference standard or by determining the absorption at 280 nm in 6 M guanidinium chloride.
Purified PDZ domains were aliquoted, flash-frozen and stored at -80 'C in PBS (pH 7.4) until
use.
Fluorescence Studies. Fluorescence spectra were recorded on a Fluoromax 3 instrument
(Horiba Jobin Yvon) in 1 cm path length quartz cells (100 mL nominal volume from Starna
Cells). All measurements were performed at a constant temperature of 25 'C. Slit widths
were 3 nm for excitation and 6 nm for emission. The 4-DMAP fluorophore was excited at 421
nm and the spectra were recorded between 432 nm and 730 nm (0.5 nm increments and 0.1 s
integration time).
Relative Fluorescence Increases. The fluorescence increase measurements were performed at
25 'C in PBS buffer (pH 7.4) comparing solutions of (1) 10 [M of 4-DMAP-containing
peptide alone in PBS and (2) 10 tM of 4-DMAP-containing peptide with 20 1 M of PDZ
domain construct in PBS. Blanks consisting of PBS for (1) and PBS with 20 tM of the
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corresponding PDZ domain construct for (2) were subtracted from the respective spectra. The
fluorescence increase for each series of peptide and PDZ domain construct was evaluated by
comparing the fluorescence emission intensities of (2) and (1) at the wavelength of maximal
emission of (2). Ratios were calculated over a 5 nm range centered on the wavelength of
maximal emission of (2) and the values were averaged to yield the reported final ratio.
Fluorescence Titrations. For each titration, the peptide concentration was kept constant (5
[tM) and the protein concentration was varied from values lower than or close to the
anticipated KD to saturation of the fluorescence signal increase. A 150 tL solution in PBS
(pH 7.4) was prepared for each protein concentration. Dissociation constants were evaluated
using SPECFIT/32TM Global Analysis System for Windows (version 3.0.39) after averaging
at least three independent titrations and taking into account wavelengths from 432 to 730 nm.
Injections in C. elegans. Researchers in the Maricq laboratory performed pseudocoelomic
injections on multiple worms expressing a GLR1-GFP construct. A 3 mM stock solution of
either peptide 16, 17, or 18 was injected into the worm. After a short incubation time, the
localization and clustering of the GFP signal in the worms was imaged and recorded.
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Chapter 6
Development and Evaluation of Dimeric Chemical Probes
for the C. elegans Glutamate Receptor Complex
Introduction
Neurotransmission is achieved through signaling between synapses, which is partially
mediated by a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs).
In vertebrates and Caenorhabditis elegans (C. elegans), these receptors are associated with
tetraspanning transmembrane proteins (TARPs), which are necessary for receptor function.
C. elegans is a multicellular eukaryote that serves as an ideal model system for higher
eukaryotes. The worm is one of the simplest organisms with a nervous system, and the
connectivity and functions of its 302 neurons has been completely mapped, making it an ideal
organism for in vivo neurobiological investigations. The critical components of the C.
elegans AMPAR complex, including TARPs STG- 1 and STG-2, are depicted in Figure 6.1.
Synaptic transmission in C. elegans, mediated by glutamate-gated current (current evoked by
stimulation with glutamate) depends on four proteins: C. elegans Stargazin-like proteins
(STG-1 and STG-2), suppressor of lurcher movement defect protein (SOL-1), and glutamate
receptor family protein (GLR-1). 3 STG-1 and STG-2, although distantly related by primary
sequence to vertebrate TARPs, can functionally substitute for vertebrate TARPs in
reconstitution experiments, displaying evolutionarily conserved roles for TARPs in the
regulation of AMPARs. STG-1 and STG-2 can also substitute for one another in functional
C. elegans receptors. Studies have clearly shown that STG- 1 and STG-2 are necessary for the
proper function of the GLR-1 receptor, since glutamate-gated current is not observed in the
absence of these two proteins.4 However, the exact functions of these TARP auxiliary
proteins and their chemical modes of interaction with the GLR-1 receptor remain unclear.
Further elucidation of the roles of these proteins in C. elegans may help to provide insight into
the interactions and functions of vertebrate glutamate receptor complexes.
121
Figure 6.1. Proteins involved in the function of the ionotropic glutamate receptor GLR-1
complex in C. elegans.
Although the modes of interaction between GLR-1, SOL-1, STG-1, and STG-2 are
currently unknown, it is possible that they interact via a PDZ domain-containing protein (to
which the C-terminus of STG-2 binds). The C-terminus of STG-2 is a putative PDZ domain
ligand, with a conserved hydrophobic C-terminal residue (see Figure 6.2). The Stargazin
homologue of STG-2 in vertebrates is a known PDZ domain ligand, hence STG-2 may
interact with a PDZ domain-containing protein as well. Note that, although STG-1 and STG-
2 are functionally related in C. elegans, the STG-1 C-terminal sequence does not resemble a
canonical PDZ domain ligand (Figure 6.2). For this reason, STG-2-mediated interactions
were targeted in this study.
The interactions of the C-terminus of STG-2 may play a critical role in its function and
also in the clustering of GLR-1, SOL-1, and STG-2 proteins of the AMPAR complex in C.
elegans, similar to the role Stargazin plays in vertebrates. Dimeric Stargazin-based probes for
the rat neuronal system have been utilized successfully to disrupt the Stargazin - PDZ domain
interaction.' Specifically, dimeric probes (as opposed to the corresponding monomeric
counterparts) are necessary to disrupt the native interactions, since Stargazin ligands bind
cooperatively to the tandem PDZ domains (PDZ1 and PDZ2) of PSD-95. Tandem PDZ
domains, which are linked closely together within a protein (typically about 9-12 residues
apart), are known to bind synergistically to their target ligands; PDZ domains can also work
together in concert by dimerization or multimerization (see Figure 6.3 for a schematic
comparison). Synergistic binding of multiple PDZ domains thermodynamically enhances the
binding affinity between PDZ domains and target monomeric ligands.6 The presentation of
two ligands in the form of a dimer mimics the stronger native multivalent interaction through
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the same thermodynamic principles. Since Stargazin and STG-2 are evolutionarily conserved,
it is likely that STG-2 may exhibit similar multivalent binding interactions with a PDZ
domain-containing protein. This chapter describes the synthesis and evaluation of dimeric
probes based on STG-2, designed to disrupt the binding of the STG-2 C-terminus to either
monomeric or dimeric partner PDZ domains in C. elegans.
-14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0
Stargazin (309-323) D S L H A N T A N R R T T P V COOH
STG-1 (352-366) R R F A I P V S Q G Y P S L S COOH
STG-2 (365-379) Q A S F S N P S L L F M Q D V COOH
STG-2 Dimer N R R Y S N P S L L F Nie Q D V cOOH
Figure 6.2. Alignment of R. norvegicus Stargazin (Uniprot Q71RJ2), C. elegans STG-1
(Uniprot Q7YX75), and C. elegans STG-2 (Uniprot D9N123) C-terminal 15 residues. The
sequence used for the dimer based on STG-2 is also shown (last entry); the presence of the
tyrosine (Y) residue allows for quantification, and the NRR residues aid in solubility, since the
C. elegans STG-2 C-terminal sequence is rather hydrophobic. Note that the methionine
residue in the dimer entry is replaced with the isosteric norleucine in the dimer sequence, due
to complications with methionine oxidation.
Results and Discussion
6-1. Design of dimeric competitor for STG-2 protein
The binding partner(s) of C. elegans STG-2 are currently unknown, although the C-
terminus of STG-2 (Figure 6.2) is a putative PDZ domain ligand. The chemical interaction
between STG-2 and the GLR-1 complex in the worm model system is unknown, hence
investigations were undertaken to determine whether or not the C-terminus of STG-2 is a
critical component of this interaction.
PDZ domain dimer PDZ domain tandem
Figure 6.3. Schematic of dimer versus tandem PDZ domains.
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As discussed above, it has been shown that dimeric Stargazin-based PDZ domain
ligands have been used successfully to out-compete out native multivalent interactions
between Stargazin and PSD-95 in rat neurons. In this case, since the native interaction was
multivalent (involving the binding of Stargazin ligands to a tandem of two PDZ domains),
monovalent Stargazin-based ligands were not capable of inhibiting the native interaction.
Based on these results, a dimeric ligand of the Stargazin-related protein STG-2 was pursued.
If STG-2 is not involved in multivalent interactions, but instead binds a partner PDZ domain
in a monovalent fashion, as opposed to a multivalent interaction, the STG-2 dimer would still
be capable of competing for this binding site, since it is composed of two monomeric units.
In this scenario, the higher local concentration of monomer presented by the dimeric ligand
could potentially enhance its ability to inhibit an interaction between STG-2 and the single
PDZ domain. Both monovalent and multivalent modes of STG-2 interactions can therefore
be probed with the STG-2 dimer, and these models are illustrated graphically in Figure 6.4.
124
PDZ domain
tandem or dimer
PDZ domain
STG-2
dimeric
ligand
Figure 6.4. Schematic of the proposed STG-2 dimeric ligand function. The dimeric ligand
should out-compete interactions between the STG-2 C-terminus and PDZ domain(s) in either
a multivalent or monovalent fashion. Note that multivalent interactions can arise between the
ligand and either a tandem of PDZ domains (located within the same protein macromolecule)
or a dimer or multimer of single PDZ domains from multiple proteins.
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While the fluorescence-based monomeric probes developed for PDZ domains
(described in detail in Chapter 2) demonstrated native sequence specificity with the
incorporation 10 native PDZ domain ligand amino acid residues, the linker length
considerations for dimeric probe design introduce an added layer of complexity. As depicted
in Figure 6.5, dimeric ligands with too short of a linker length would not be able to bind both
PDZ domains simultaneously, and dimeric ligands with longer linkers might have to pay an
entropic penalty and consequently behave more like monomers in solution.
optimal
dimeric ligand
length
shorter linker longer linker
PDZ domain
tandem
Figure 6.5. Schematic of the importance of linker length for the function of dimeric probes.
Previous studies have shown that dimeric ligands based on the Stargazin C-terminal
sequence, composed of 15-residue monomeric units, were most effective at binding to the
PSD-95 tandem PDZ domains in rat neurons.5 With the hypothesis that the homologous
TARPs, Stargazin and STG-2, share similarities in their cognate protein domains and binding
modes, monomers of 15 residues were used to construct STG-2 dimers for the C. elegans
target (see Figure 6.2). The STG-2 dimer was modified from the C. elegans STG-2 sequence,
as shown in Figure 6.2; a tyrosine residue (replacing a phenylalanine residue) allows for
quantification of the peptide by UV absorption analysis, and the NRR (Asn-Arg-Arg)
sequence appended to the N-terminus aids in the solubility of the fairly hydrophobic peptide.
The application of these probes to studies in vivo necessitates a method of delivering
the exogenous ligands into cells. Therefore, the probes were designed to incorporate a cell
penetrating peptide sequence. Specifically, the HIV-1 TAT sequence (TAT 47 57,
YGRKKRRQRRR) was utilized for this purpose,' since it has been shown to confer cell
permeability to covalently-attached cargo. This sequence could be incorporated at the N-
terminus of one of the dimer "arms," far enough from the critical PDZ ligand - PDZ domain
interactions to avoid interfering with binding of the dimer. A schematic of this general design
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is shown in Figure 6.6, and details of the synthetic routes pursued and the optimized dimer
synthesis will be presented in section 6-2. In general, the monomeric units are linked at their
N-terminal residues to yield a dimer with two free carboxylic acids at the C-terminal amino
acids; click chemistry of the alkyne of one monomer with the azide of another yields a
triazole linker. The ability to further extend one of the monomeric units of the dimer (through
reaction with a free N-terminus after click chemistry) is critical to the design of the probe,
since this allows for covalent linkage of the TAT sequence to the dimer.
Figure 6.6. Modular TAT-modified dimeric ligand design. Note the presence of the triazole
in the linker, which results from the click chemistry ligation of the monomeric units.
A control dimeric ligand of similar design was also pursued. The TAT-control dimer
would be used for in vivo analyses to control for any non-specific or toxic effects of the TAT
sequence. The peptide sequence designed for the control is shown in Figure 6.7, aligned with
the corresponding STG-2 residues. Multiple design features of the control sequence should
exclude binding of the control to PDZ domains. Firstly, the C-terminal amide (in place of
the C-terminal carboxylate) should greatly reduce binding to any PDZ domain, since the C-
terminal carboxylate of PDZ domain ligands forms critical contacts within the PDZ domain
binding stie. The arginine residue at the conserved 0 position replaces a residue that is
canonically hydrophobic in all classes of PDZ domain ligands, and should not be tolerated in
PDZ domain binding sites. Together with the multiple arginine residues at other positions
near the C-terminus, these elements should render the probe unable to bind to any PDZ
domain.
-14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0
STG-2 Dimer N R R Y S N P S L L F Ne Q D V cooHControl Dimer Y S L H A N T A N R R T R P R NH2
Figure 6.7. Modified STG-2 sequence used for monomeric units of the TAT-STG-2 dimer,
and control sequence used for monomeric units of TAT-control dimer.
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6-2. Synthesis of TAT-STG-2 dimer and TAT-control dimer
Previous unpublished results from the Imperiali laboratory have shown that an on-
resin [3+2] dipolar Cu(I)-catalyzed Huisgen cyclization ("click" chemistry)9 approach to
forming triazole-linked dimeric PDZ domain ligands is favorable relative to click chemisty in
solution. This is mainly due to solubility limitations of the monomers and the resulting dimer,
which are often fairly hydrophobic (see STG-2 dimer entry, Figure 6.7), as well as the higher
effective concentration of alkyne- and azide-modified peptides that are realized in an on-resin
approach. Therefore, an on-resin synthetic approach was explored.
Two possible synthetic routes are presented in Schemes 6.1 and 6.2, which differ in
the mode of TAT sequence introduction onto the dimeric peptide. In route A, the TAT
sequence is incorporated via native chemical ligation, after the dimers have been synthesized
and purified. This route has been utilized previously,5 and can be advantageous since the
dimer and TAT-thioester are purified before introduction of the TAT sequence, hopefully
yielding a more pure TAT-dimer product before the final HPLC purification. In route B, the
TAT sequence is incorporated via standard solid phase peptide synthesis before click
chemistry. This route has fewer synthetic steps overall, and can be advantageous when the
dimeric peptides alone are hydrophobic and not very soluble.
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Scheme 6.1. Synthetic Route A, two variations.
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Scheme 6.1. Synthetic Route A, two variations. Native chemical ligation after dimerization
to introduce the TAT sequence, using either Fmoc-homopropargyl glycine 2 and 5-
azidopentanoic acid 3 as the alkyne and azide (top) or Fmoc-Lys(N 3) 8 and 4-pentynoic acid 9(bottom). Note: SPPS = solid phase peptide synthesis, reagents and conditions are described
in the Experimental Methods section.
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Scheme 6.2. Synthetic Route B.
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Scheme 6.2. Synthetic Route B. Standard SPPS before dimerization to introduce the TAT
sequence. Note: SPPS = solid phase peptide synthesis, reagents and conditions used are
described in the Experimental Methods section.
The options in synthetic in route A were examined first, since the intermediates 5 and
11 are HPLC purified before reaction with purified TAT thioester, which should aid in the
final TAT-dimer purification. Homopropargyl glycine 2 and Fmoc-Lys(N 3) 8 were
synthesized according to published literature procedures,10' 11 until Fmoc-Lys(N3) became
commercially available during the time period of our investigations. Initial testing revealed
that the click chemistry reaction between 8 and 9 was higher yielding than the reaction
between 2 and 3 in the context of test peptides. However, the STG-2 dimeric ligand 11 was
too hydrophobic to dissolve in aqueous media, even with up to 10% dimethylformamide. The
intermediate HPLC purification of the STG-2 dimeric ligand 11 was therefore not possible,
and neither was the subsequent native chemical ligation reaction to yield compound 12. This
led to the exploration of synthetic route B.
Synthetic route B (Scheme 6.2) was successfully implemented for the formation of
TAT-STG-2 and TAT-control dimers, and the full details of both dimeric ligand syntheses are
described in the Experimental Methods section of this chapter. Note that for the synthesis of
the control dimeric peptide, PAL-PEG-PS resin is used to afford C-terminal amides.
Appendage of the basic TAT sequence via solid phase peptide synthesis (SPPS) before click
chemistry avoided the STG-2 dimer solubility issues. For the synthesis of the TAT-control
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dimer, optimizations to the SPPS conditions were necessary, as the major product initially
observed was a truncation product (residue incorporation halted after coupling of the third
TAT amino acid). At that point, 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HATU) and 1-hydroxy-7-azabenzotriazole (HOAt) were explored as
peptide coupling reagents in place of O-Benzotriazole-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU) and N-Hydroxybenzotriazole (HOBt). The HATU aza
derivatives have been shown to be more efficient than HBTU, especially in syntheses
involving hindered amino acids. Indeed, triple coupling of the TAT sequence residues with
HATU/HOAt yielded the completed target sequence.
Since the azide, 8, and the alkyne, 9, are coupled onto the resin simultaneously in this
synthesis, optimization of the ratio of each of these precursors to the resin was necessary. In
initial trials, 4:3 equivalents of 8:9 were used, with the expectation that the more bulky
reagent, 8, might not couple quite as efficiently as precursor 9. While this was indeed true,
under these conditions very little of the coupling product with azide 8 was available for
extension with the TAT sequence. In order for the dimerization to proceed with a reasonable
yield, the TAT-azide-monomer and alkyne-monomer needed to be present in fairly equal
quantities. Multiple different ratios of these compounds in the coupling step were therefore
tested. Comparisons were made after the click chemistry step by preparative HPLC analysis
of resulting TAT-dimer and excess unreacted alkyne-monomer. The results from these
optimization studies are summarized in Table 6.1. Ultimately, the ratio of 3:1 (azide 8:
alkyne 9) led to both a low amount of excess alkyne-monomer and the highest yield of TAT-
dimer.
Entry Ratio of reaqents Resultab
8: 9:resina
1 4:3:1 monoeer, >> TT-dime
2 6:2:1 monamr, > TAT-dimr
3 3:1:1
4 2:1:1 monamr, < TAT-dimr
5 2:0.75:1 monamr, < TAT-d4 r
Table 6.1. Optimization of the ratio of 8:9 used in the coupling step of the dimer synthesis.
The optimal ratio was found to be 3:1, as highlighted in the table. a Ratio of equivalents of 8
and 9 with respect to the resin. b monomer = alkyne monomer unit; comparative analysis of
excess monomer and TAT-dimer resulting from click chemistry.
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During initial HPLC analysis, it was observed that the TAT-azide-monomer and TAT-
dimer eluted under similar conditions. The following HPLC conditions were found to be
optimal for the separation of TAT-dimer from excess monomer. For TAT-STG-2 dimer, the
gradient was 5-25% acetonitrile containing 0.1% TFA for 6 min followed by 25-45%
acetonitrile containing 0.1% TFA over 70 min in water containing 0.1% TFA at a flow rate of
10 mL/min. For TAT-control dimer, the gradient was 5-10% acetonitrile containing 0.1%
TFA for 6 min followed by 10-25% acetonitrile containing 0.1% TFA over 70 min in water
containing 0.1% TFA at a flow rate of 10 mL/min. Typically, two to three rounds of
purification were necessary.
After multiple rounds of purification, ESI-MS and MALDI-TOF analyses show
significantly reduced monomer signals as compared to the dimer signal. Analytical HPLC
allowed for resolution of the monomer and dimer signals, hence final TAT-STG-2 and TAT-
control dimeric ligand purity (>95% dimer) could be confirmed by analytical HPLC (see
Figure 6.8 below).
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Figure 6.8. Dimer HPLC traces. Top: TAT-STG-2 dimer, >95% pure by 280 nm analytical
HPLC trace; X = norleucine. Bottom: TAT-control dimer, >95% pure by 280 nm analytical
HPLC trace.
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Overall, the desired dimeric peptides were successfully synthesized and purified, and
their characterization is presented in Table 6.2. While only small amounts of very pure
material were produced, it was estimated that 0.15 jimol of each dimeric ligand would allow
for multiple tests in over 200 worms; 0.16 [Jmol of the TAT-STG-2 dimer and 0.22 [tmol of
the TAT-control dimer were obtained. These compounds were lyophilized into 0.02 [tmol
aliquots and sent to the Maricq laboratory for testing in C. elegans, which will be described in
section 6.3.
Entry Peptide Molecular Formula Mass ES1 Mass MALDI Mass t m
expected obtained obtainedINN]j [IBM] -
1 T&T-STG-2 C23923 89Na0 6, 5462.4 1093.65+, 5461.6 59.5
911.44+
2 TAT-control C22-B3 63N9 0B,6  5444.3 1089.75*, 5437.9 36.8
908.7"*,
778.73+,
681.52+
Table 6.2. Characterization of dimers synthesized. a Retention time from analytical reverse
phase HPLC (YMC Ci8, ODS-A 5/120, 250x4.6 mm) using the following gradient: 5-10%
acetonitrile containing 0.1% TFA for 6 min followed by 10-60% acetonitrile containing 0.1 %
TFA over 70 min in water containing 0.1% TFA at a flow rate of 0.9 mL/min.
6-3. Testing of probes in vivo in C. elegans
In collaboration with the Maricq laboratory, the STG-2 dimeric peptide was tested for
its ability to disrupt GLR-1 mediated current in C. elegans. The complex of GLR-1, STG-2,
and SOL- 1 was reconstituted in C. elegans muscle, and the effect of the STG-2 dimeric
peptide on current inhibition was tested. Proper function of the GLR-1 glutamate receptor is
dependent upon its interaction with STG-2 and SOL-1, and disruption of these auxiliary
subunits of the receptor complex has been shown to inhibit glutamate-gated currents. 4
Therefore, if the STG-2 C-terminal sequence is part of a critical interaction within the GLR-1
complex, the STG-2 dimeric inhibitor should disrupt this interaction and the GLR-1 synaptic
currents.
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Electrophysiological measurements were gathered after delivery of the TAT-STG-2 or
TAT-control dimeric peptide to the C. elegans muscle via patch-clamp techniques, as
previously described.'2 The peptide was diluted to a final concentration of 25 [tM in internal
cellular fluid and patched into the muscle; glutamate was applied and currents were recorded
beginning 1-2 minutes after introduction of the peptide. Initial results from multiple
recordings show that the current response of the GLR-1 receptors to glutamate is indeed
reduced after application of the TAT-STG-2 dimeric peptide (in comparison to the current
response after application of TAT-control dimeric peptide). Figure 6.9 shows a sample of the
currents from voltage-clamped body wall muscle cells after application of either TAT-STG-2
or TAT-control dimeric peptide, and also the mean peak current responses from multiple
trials.
GLR-1 STG-2 SOL-1
+ TAT-control peptide
GLR-1 STG-2 SOL-1
+ TAT-STG-2 peptide
50 pA
1s
200 -
a.
-oV
a 100-
E
0 -
0/
Figure 6.9. Current responses to glutamate, from voltage-clamped body wall muscle cells.
A) Current responses of worms treated with (left) TAT-control dimeric peptide and (right)
TAT-STG-2 dimeric peptide. Duration of glutamate application is signified by the horizontal
bar above each current record. B) Mean peak current responses to glutamate application (t
standard error of the mean); n = 4.
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The results garnered from these experiments are promising, suggesting that the C-
terminus of STG-2 is indeed critical to the function of the GLR-1 receptor complex.
However, while this experimental approach allows for clean electrophysiological
measurements due to the high copy numbers of the reconstituted receptor complex in the C.
elegans muscle, the concentrations of protein in this system are much higher than they are in
the native system. Additionally, there may be other scaffolding proteins that play critical
roles in the GLR-1 receptor complex function, which are not present in the C. elegans muscle.
Therefore, future investigations should focus on the testing of the dimeric peptides in the
native C. elegans system (with endogenous levels of all proteins present), most likely with
specific focus on the well-characterized AVA neurons. This pair of neurons is required for
backward movement in the worm, and therefore behavioral phenotypic analysis could also be
coupled with electrophysiological investigations.
Conclusions
The on-resin syntheses of C. elegans TAT-STG-2 and TAT-control dimeric probes
have been developed and optimized, as reported here. The dimeric probes have been
successfully utilized in initial investigations in C. elegans, specifically with the aim of
understanding the protein components of the GLR- 1 receptor complex, their interactions with
each other and with other proteins, and the functional significance of these interactions.
Electrophysiological investigations with the STG-2 dimeric peptide have begun to shed light
on the critical components governing GLR-1 receptor complex function. Specifically, the
current response of the GLR-1 receptor to glutamate is significantly reduced in the presence
of the TAT-STG-2 dimeric inhibitory peptide. While these results are a first step toward
better understanding the role of STG-2 in the GLR-1 protein complex, the binding partner of
the STG-2 C-terminus (and the TAT-STG-2 dimeric peptide) remains unidentified. The
targeted interaction most likely involves a PDZ domain, and future work should focus on the
identification of this protein as well as the role it plays in the function of the GLR-1 complex
as a whole.
135
Experimental Methods
Optimal Synthesis of TAT-STG-2 Precursor Monomers. Syntheses were performed on a
0.04 to 0.02 mmol scale with Fmoc-Val-NovaSyn@ TGT resin (0.2 mmol/g), using standard
Fmoc-protected amino acid (6 equivalents), HBTU/HOBt as coupling reagents except where
indicated differently (6 equivalents each), and DIPEA (12 equivalents) in DMF or NMP.
Fmoc group removal was performed with a 20% solution of 4-methyl-piperidine in DMF
(vol/vol) for 3 x 5 minutes. Capping with an acetyl group was achieved by using an acetic
anhydride/pyridine solution (0.15 M each in DMF).
Ac-TAT-Lys(N 3)-STG-2 and alkyne-STG-2 monomers were synthesized on one batch
of resin using an automated synthesizer (Applied Biosystems Inc. automated synthesizer
model 431A) by using "difficult chemistry" Fmoc-based solid phase peptide synthesis
procedures (double coupling, 100 minutes each, and 4 x 5 minutes Fmoc-deprotection before
each coupling step). A mixture of Fmoc-azidolysine (Anaspec) and 4-pentynoic acid was
coupled onto the resin after the STG-2 peptide residues were added, at an optimal ratio of 3:1
(azide:alkyne) equivalents as compared to the resin. This yielded a mixture of azide-
containing and alkyne-containing monomers, with only the azide-containing monomers
available for further Fmoc deprotection and extension. Further "difficult chemistry" synthesis
allowed for the covalent addition of the TAT peptide residues at the N-terminus of the azide-
containing monomer, which was acetyl capped at the end of the synthesis.
Optimal Synthesis of TAT-Control Precursor Monomers. Syntheses were performed on a
0.04 to 0.02 mmol scale with Fmoc-PAL-PEG-PS resin (0.2 mmol/g), using standard Fmoc-
protected amino acid (6 equivalents), HBTU/HOBt as coupling reagents except where
indicated differently (6 equivalents each), and DIPEA (12 equivalents) in DMF or NMP.
Fmoc group removal was performed with a 20% solution of 4-methyl-piperidine in DMF
(vol/vol) for 3 x 5 minutes. Capping with an acetyl group was achieved by using an acetic
anhydride/pyridine solution (0.15 M each in DMF).
The 15-mer control sequence of the monomers was synthesized using an automated
synthesizer (Applied Biosystems Inc. automated synthesizer model 43 1A) by using "difficult
chemistry" Fmoc-based solid phase peptide synthesis procedures (double coupling, 100
minutes each, and 4 x 5 minutes Fmoc-deprotection before each coupling step). A mixture of
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Fmoc-azidolysine (Anaspec) and 4-pentynoic acid was coupled onto the resin after the control
sequence residues were added, at an optimal ratio of 3:1 (azide:alkyne) equivalents as
compared to the resin. This yielded a mixture of azide-containing and alkyne-containing
monomers, with only the azide-containing monomers available for further Fmoc deprotection
and extension.
Addition of the TAT sequence to the azide-control monomer using the method
described for the STG-2 peptide synthesis did not provide the desired compound, but instead a
truncation product. Therefore, the TAT sequence was added via triple coupling steps with
HATU/HOAt coupling reagents (6 equivalents each) on an automated synthesizer (Advanced
ChemTech automated synthesizer model 396 0), and this monomer was acetyl capped.
Click Chemistry Ligation and Purification. The Ac-TAT-azide- and alkyne-containing
monomers (for both the TAT-STG-2 and the TAT-control dimers) were then ligated via Cul-
catalyzed 1,3-dipolar cycloaddition (click chemistry) 9 on resin. Ligation was performed in
the dark overnight by addition of Cul (55 mM, 5 equiv.) and ascorbic acid (5 equiv.) in
DMF/4-methyl-piperidine (8:2, dried by bubbling with Argon) to the resin. After overnight
shaking, the resin was dried. Drying of the resin and exposure to air resulted in a bluish tint to
the resin, which was attributed to excess copper coordinated to the resin. Therefore, it was
washed with 5 x 5 mL sodium diethyldithiocarbamate trihydrate (Et 2NCSSNae3H 20, 1%
w/v), containing 1% DIPEA (v/v) in DMF to remove excess coordinated copper.13 This was
repeated 3-5 times until the resin was no longer blue or dark brown, and then the resin was
washed extensively with DMF.
Peptides were deprotected and cleaved from the resin with a TFA/H 20/TIPS
(95:2.5:2.5) cleavage cocktail for 2.5 to 3 hours. TFA was evaporated until the peptides
precipitated. The peptides were then triturated and precipitated in cold ether before
purification by reverse phase HPLC on a semi-preparative column (YMC-Pack Pro C18, ODS-
A 5/120, 250x20 mm) in water (0.1% TFA) using an acetonitrile (0.1% TFA) gradient and
monitoring at 228 nm and 280 nm. Purification was performed on 0.02 mmol or less of
material at once, due to solubility and difficulty of HPLC separation of dimer from
monomeric species. Typically, three rounds of HPLC purification were necessary to achieve
pure (>95%) dimer. Peptides were stored lyophilized at -80 0C until use.
137
Peptide Characterization and Quantification. Peptide identity was confirmed by MALDI-
TOF mass spectroscopy (MALDI-TOF, PerSeptive Biosystems Voyager) using DHB as a
matrix, and by ESI-MS analysis. Purity was assessed by analytical reverse phase HPLC
(YMC C18 , ODS-A 5/120, 250x4.6 mm) using a standard gradient (5-10% acetonitrile
containing 0.1% TFA over 6 minutes followed by 10-60% acetonitrile containing 0.1% TFA
over 71 minutes in water containing 0.1% TFA at a flow rate of 0.9 mL/min). The final
peptides were quantified using molar extinction coefficients of the peptides (each peptide
contained at least one tyrosine residue, in order to allow for this quantification).
Patching into Reconstituted C. elegans Muscle Cells, and Electrophysiology. All recordings
were obtained from the body wall muscles of adult worms. For the worm preparation,
histoacryl glue was applied to the dorsal aspect of worms on glass coverslips. A lateral
incision was made along the length of the body, the flap of cuticle was glued down, and the
intestine and gonad were removed. The preparation was then washed briefly (about 30
seconds) with a solution of 1 mg/mL collagenase (Sigma Type IV) in extracellular fluid. The
extracellular fluid consisted of 150 mM NaCl, 5 mM Kcl, 4 mM MgCl 2 , 1 mM CaCl2, 15 mM
HEPES, and 10 M glucose (pH 7.4, osmolarity adjusted with 20 mM sucrose). A HEKA
EPC-9 patch-clamp amplifier was used for whole-cell voltage-clamp recordings from muscle
cells. Recording pipettes were fire polished to a resistance of 3-6 MQ and filled with an
intracellular fluid solution consisting of 115 mM K-gluconate, 25 mM KCl, 0.1 mM CaCl 2,
50 mM HEPES, 5 mM Mg-ATP, 0.5 mM Na-GTP, 0.5 mM cGMP, 0.5 mM cAmp, and 1
mM BAPTA (pH 7.4, osmolarity adjusted with 10 mM sucrose).
Lyophilized peptide was diluted to a final concentration of 2 mM in diH20, and this
was diluted to a final concentration of 25 tM in intracellular fluid in the micropipette. About
1-2 minutes after breaking into the cells with the micropipette, 3 mM glutamate was applied
via pressure application, and voltage-clamp recordings were made.
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Appendix 1
Development of a Sox-Based Sensor for
Calmodulin Kinase II (CaMKII) Activity
Introduction
Calmodulin kinase 1I (CaMKII), a Ser/Thr protein kinase, comprises about 2% of the
total protein in the hippocampus of rodents, and is thought to play crucial roles in long-term
potentiation (LTP) and long-term depression (LTD), modulations in synaptic strength that
govern learning and memory.' The current activity probe most widely used is an 88-residue
sequence (vimentin, which is specifically phosphorylated by CaMKII) tagged with a GFP
fluorophore.2 Ratiometric analysis of phosphovimentin antibody staining and GFP
fluorescence is needed to quantify kinase activity from the application of this probe. Work
has been done toward the development of a more straightforward sensor that could eventually
be used in neurons to detect CaMKII activity, and will be described here.
The sulfonamido-oxine (Sox) chromophore previously developed in the Imperiali
laboratory has been successfully placed in kinase recognition motifs containing a Ser or Thr
residue; upon phosphorylation of optimized sensors, the affinity of the chemosensor for
Mg(II) increases, and chelation-enhanced fluorescence is observed.3'4 To develop sensors for
CaMKII based on this design, CaMKII recognition motifs from both "syntide" and NR2B
were utilized, since these are two of the highest-affinity binding partners of CaMKII present
in the PSD.' Short peptides of each of these recognition motifs were previously characterized
via kinetic analysis as suitable substrates for CaMKII.'
Results and Discussion
Al-i. Sensor Development and Design
Sensors based on the NR2B and syntide sequences were synthesized, with
introduction of the Sox chromophore as the amino acid C-Sox 1 (see Figure Al.1), at the
positions shown in Table A1.1. 4 The N- and C-termini of the peptides given in the literature
were truncated, in order to make the sensors both easier to prepare and handle and also
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hopefully less promiscuous with respect to recognition by off-target kinases. Both the Ser and
phosphoserine (pSer) analogs of the peptides were synthesized, and the robust fluorescence
increases between the phosphorylated and non-phosphorylated peptides are displayed in Table
A1.1.
SO2N(CH 3)2
COO-
N NH3+
OH
Figure A1.1. Sox-derived amino acid building block for peptide synthesis.
# Origin Peptide Sequence* Fomul Mass Magsh Me
expected obtained
S_[M1*
1 Syntide ACARTLSVIGL)GK- C63 310 4NIsOVIS 2  1507.3 1507.2 -
2 Syntide ,_ARTLpSVGLPGK--Q C6 3 B10 4N1gO2 1P1S2  1586.3 1586.2 5.4 (4.9)
3 NR2B _KLRQHSYC-TV_,N- CAUB2 4O021S 2  1843.7 1845.0 -
4 1NR2B IKLRRQHpSY0TIV_- C2UB1N 2 40 2 4P1S 2  1922.7 1923.4 5.3 (4.5)
Table A1.1. Sensor sequences and their fluorescence increases at 485 nm. a = C-Sox
residue. b Masses were determinated by MALDI-TOF spectroscopy. C RFI = Relative
fluorescence increase of pSer sensor over Ser sensor at 485 nm, values in parentheses are the
RFI in the presence of ATP.
The fluorescence increases of the Sox chromophore between phosphorylated and non-
phosphorylated substrate sequences were promising, since they were in the range typically
found for successful Sox-based kinases sensors. These fluorescence increases were also
robust in the presence of ATP, which is present both in kinase assay conditions as well as the
cellular environment. Therefore the sensors were both validated with recombinant CaMKII
kinase and tested for kinetic competency.
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AJ-2. Sensor Validation
In order to test the initial sensors with CaMKII, it was first necessary to test kinase
competency. CaMKII (truncated monomer of the c subunit, Rat, Recombinant, S. frugiperda
Sf9, NEB) was used, and multiple dilutions were tested. Table A1.2 below shows the
competency tests (with 0.5 tM substrate 3) for the chosen dilution conditions (10-fold
dilution of kinase prior to activation, followed by 10-fold dilution of kinase following
activation). The activation procedure for the kinase is described in detail in the Experimental
Methods section.
Entry ng CaMII Slope Sl
1 1 2307 163 1.00
2 0.5 1128 172 0.49
3 0.25 607 * 152 0.26
Table A1.2. Recombinant kinase competency tests. Each entry is the average of three trials.
a Ratio of slope with that of Entry 1.
Sensors 1 and 3 were carried on in assays with the recombinant kinase, and the results
of these assays are summarized in Table A1.3. Substrate 1 did not display favorable kinetic
properties, with a Km of greater than 70 tM, much higher than the reported literature value for
the parent syntide peptide. However, multiple assays of substrate 3, the results of which are
averaged and presented in entry 4 of Table A1.3, showed favorable kinetic properties
comparable to those reported in the literature. Specifically, sensor 3 and the parent peptide
reported in the literature displayed the same affinity (Kn) for CaMKII, and the rates of
catalytic efficiency (Vna) were also comparable. Magnesium titrations yielded a dissociation
constant of 7.17 mM ± 0.51 mM for sensor 3 and Mg 2+. This most likely indicates that
supplementary Mg 2+ would be necessary for this sensor to optimally detect CaMKII activity
in vivo, since the typical concentration of this cation is about 1 mM in neurons. However, this
is feasible, and due to the favorable kinetic properties observed, sensor 3 was further
developed through analysis in cross-reactivity studies.
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Entry Origin ng X nano (pM) Vm (km ) kcat/X
____ ____ __ _ ____ __ _ ____ ____ (smol/minmg) _ _ _ _ _ _ _
1 Syntide - 13.4 * 1.8 2.0 * 0.25 15.4 * 4.1
2 Syntid. 10 71 1.9 0.03
3 VI2 - 0.29 * 0.1 0.62 * 0.16 2.25 * 0.29
4 NR2B 0.9 0.29 a 0.02 1.6 * 1.0 5.4 * 2.9
Table A1.3. Kinetic assays of substrates. a Literature values for parent
in entries 1 and 3,1 to be compared with entries 2 and 4, respectively.
peptides are displayed
A]-3. Cross Reactivity with Other Kinases
Due to the favorable kinetic properties of sensor 3, cross-reactivity studies with other
kinases were performed to establish selectivity. Specifically, PKA and isoforms of PKC were
chosen for the initial selectivity tests, as these kinases are expected to be prevalent in
neurons.5 Figure A1.2 shows the results of these studies, represented as reaction rates (slopes)
normalized to that of 0.5 M sensor 3 + CaMKII. All of these studies were done using 1 ng
kinase.
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Figure A1.2. Normalized cross reactivity of PKC isoforms and PKA with sensor 3.
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At the lower 0.5 ,M concentration, near the Km of sensor 3, CaMKII is more than 3-
fold selective for the sensor over PKA and the PKC isoforms. It is noteworthy that while
PKC and PKA activities drop down as the sensor concentration is lowered, CaMKII activity
basically remains steady. Introduction of the sensor at this low concentration in neurons
should allow for low background phosphorylation by these PKC isoforms, provided that they
are present at equal or lesser concentrations than CaMKII in the neurons. Unfortunately, the
relative amount of these kinases present in neurons is unknown, and these values likely vary
greatly depending on many biochemical processes and neuronal developmental stages.
Additionally, there remain other off-target kinases to test against this sensor, including other
isoforms of PKC as well as other kinases with preferences for basic substrates (ERK, AKT,
and MK2). 68 However, thus far sensor 3 is promising for future application to neuronal
studies.
Conclusions
The design, synthesis, and in vitro analysis of an optimized Sox-based sensor for the
detection of CaMKII activity in neurons has been performed. Further analysis has shown that
the sensor is specific for CaMKII over multiple PKC isoforms, at concentrations close to the
Km of the sensor. Future work will involve additional cross-talk studies, as well as the testing
of this probe in neuronal cells, where its utility is envisioned. Specifically, the sensor has
been designed to be patched into neuronal cells, allowing for the imaging of CaMKII activity
in these cells with spatial and temporal resolution.
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Experimental Methods
Sensor synthesis and characterization. All amino acids except Fmoc-C(Sox)-OH were added
according to standard Fmoc SPPS procedures. Manual synthesis was performed on a 0.04 to
0.02 mmol scale with Fmoc-PAL-PEG-PS resin (0.2 mmol/g), using standard Fmoc-protected
amino acid (6 equivalents), HBTU/HOBt as coupling reagents (6 equivalents each) and
DIPEA (12 equivalents) in DMF or NMP. Coupling steps were conducted with a 50 mM
solution of amino acid (~l mL per 100 mg of resin) for 1 hour. Fmoc group removal was
performed with a 20% solution of 4-methyl-piperidine in DMF (vol/vol) for 3 x 5 minutes.
After removal of the N-terminal Fmoc group, the resulting free amine was capped with an
acetyl group by using an acetic anhydride/pyridine solution (0.15 M each in DMF).
Fmoc-C(Sox)-OH was coupled overnight under the following conditions:
amino acid / PyAOP / HOAt / DIPEA, 2.5:2.5:2.5:6.25, 0.15 M in DMF. Since the TNBS test
for free amines can yield false positive results after coupling of Fmoc-C(Sox)-OH, test
cleavage and MALDI-TOF-MS analysis after coupling was performed. Peptides were
deprotected and cleaved from the resin with a TFA/H20/TIPS (95:2.5:2.5) cleavage cocktail
for 2.5 to 3 hours. TFA was evaporated until the peptides precipitated. The peptides were then
triturated and precipitated in cold ether before purification by reverse phase HPLC on a semi-
preparative column (YMC-Pack Pro C18, ODS-A 5/120, 250x20 mm) in water (0.1% TFA)
using an acetonitrile (0.1% TFA) gradient and monitoring at 228 nm and 316 nm (Sox).
Peptides were stored lyophilized at -80 0C until use.
Peptide Characterization and Quantification. Peptide identity was confirmed by MALDI-
TOF mass spectroscopy (MALDI-TOF, PerSeptive Biosystems Voyager) using DHB as a
matrix. Purity was assessed by analytical reverse phase HPLC (YMC C18, ODS-A 5/120,
250x4.6 mm) using a standard gradient (5% acetonitrile containing 0.1% TFA for 5 min
followed by 5-95% acetonitrile containing 0.1% TFA over 35 min in water containing 0.1%
TFA at a flow rate of 1 mL/min). The final peptides were quantified using the molar
extinction coefficient of Sox (E355nm = 8247 M'1cm-1 in water).
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Fluorescence Experiments. Fluorescence scans were performed on a Fluoromax 3 from Jobin
Yvon. When comparing fluorescence spectra, 3 nm excitation and emission slit widths were
used. For enzyme assays, 5 nm emission and excitation slit widths were used. For all
experiments, an excitation wavelength of 360 nm was used. Enzyme assays were performed
by monitoring emission at 485 nm.
To determine the difference in fluorescence intensity of the Ser and corresponding
pSer sensors at Xma, these peptides were tested alone in buffer and in the presence 1.2 tL 100
mM ATP solution. The 1Ox stock buffer composition is as follows: 200 mM HEPES (pH 7.4)
and 100 mM MgCl 2-
Magnesium Titrations. A 500 tL solution of 1 or 10 tM pSer NR2B sensor, 150 mM NaCl,
and 20 mM pH 7.4 HEPES was made in a glass cuvette. Successive additions of MgCl 2 were
made, allowing for fluorescence emission spectra to be taken at intervals between 0.5 [tM and
300 tM MgCl 2 concentrations. Data were fit using SPECFIT/32TM Global Analysis System
for Windows (version 3.0.39).
CaMKII Preparation. According to the New England Biolabs (NEB) protocol and the
literature, prior to substrate phosphorylation, CaMKII should be activated by
autophosphorylation with ATP/Mg2 , in the presence of CaCl2 and calmodulin. Neither CaCl 2
nor calmodulin are required for the subsequent phosphorylation of exogenous substrate. The
CaMKII was activated according to the NEB protocol. Firstly, a lOx reaction buffer was
made. The 1x reaction buffer composition is as follows: 50 mM TRIS-HCl, 10 mM MgCl 2, 2
mM dithiothreitol (DTT), 0.1 mM Na 2 EDTA, pH 7.5 at 25 'C. Then 2 [tL CaMKII
(truncated monomer of the a subunit, Rat, Recombinant, S. frugiperda Sf9, NEB) (from a 2.5
[tL aliquot, stored at -80 'C) was mixed with lx reaction buffer supplemented with 100 [M
ATP, 1.2 tM calmodulin, and 2 mM CaCl2, to yield the final recommended 10-fold dilution.
After incubation for 10 minutes in a 30 *C water bath, the activated kinase was diluted an
additional 10-fold before use.
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PKA Preparation. PKA does not need pre-activation. For the reactions, a 1Ox reaction buffer
was made. The 1x buffer composition is the following: 20 mM HEPES (pH 7.4), 10 mM
MgCl 2, 1 mM DTT, 0.1 mM EGTA. Then a lOx enzyme dilution buffer was made, in which
the 1x buffer concentrations are: 50 mM Tris, 10 mM MgCl 2, 1 mM DTT, and 0.15 mg/mL
BSA. The enzyme dilution buffer was diluted to 1x, and used to dilute the enzyme solution
500-fold. Then 1 [tL PKA (from an aliquot stored at -80 'C, after dilution) was used in the
reaction.
PKC Preparation. A 1 1tL aliquot of PKCca (Human, Recombinant, Calbiochem) was diluted
with enzyme dilution buffer to the final concentration of 1 ng / tL. A l0x dilution buffer was
made, and the 1x buffer concentrations are: 20 mM HEPES (pH 7.4), 10 mM MgCl 2, 0.3 mM
CaCl 2, 10 mg/mL BSA, 0.01% Brij-35 P. For the reaction, 120 [tL of the following was made
in a cuvette: 20 mM HEPES (pH 7.4), 10 mM MgCl 2, 0.3 mM CaCl 2, 0.1 mM EGTA, 100
[M ATP, 1 mM DTT, 0.5 [g/mL phosphatidylserine, 0.1 [tg/mL diacylglycerol, 1 ng kinase.
The reaction components were mixed and incubated for 4 min at 30 'C. Substrate was added
last and mixed to begin the reaction.
Assay Monitoring (Fluorimeter). Reaction solutions were mixed 5x in the cuvette before and
after addition of the kinase, and were subsequently monitored for 10 minutes while
fluorescence was recorded every second with a 1 sec integration time (Xe, = 360 nm, kem =
485 nm, slit widths: Ex = 5 nm and Em = 5 nm). In order to correct for the intrinsic
fluorescence of the substrate in the kinase reaction, separate samples of substrate and
phosphopeptide were prepared (without enzyme) and the fluorescence was recorded under the
same conditions. Note that, for CaMKII and PKA, kinase was then added to these same
substrate samples for the reaction.
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